var title_f20_60_21440="Retrosternal goiter CT";
var content_f20_60_21440=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retrosternal goiter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 302px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan of a retrosternal goiter seen as an inhomogeneous mass anterior to the trachea. The airway is narrowed and displaced to the left and posteriorly. The aortic branches are \"peeled off\" the trachea and displaced anteriorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_60_21440=[""].join("\n");
var outline_f20_60_21440=null;
var title_f20_60_21441="BAL amiodarone lung";
var content_f20_60_21441=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    BAL in amiodarone pulmonary toxicity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bronchoalveolar lavage (BAL) cytopreparation smear with normal differential and marked foamy appearance of alveolar macrophages.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_60_21441=[""].join("\n");
var outline_f20_60_21441=null;
var title_f20_60_21442="Toe towel curls PI";
var content_f20_60_21442=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F70243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F70243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Toe towel curls",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Curl your toes around a towel. Then grip and release the towel over and over again for 1 to 2 minutes, twice a day.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_60_21442=[""].join("\n");
var outline_f20_60_21442=null;
var title_f20_60_21443="Gram stain sputum 2A answer";
var content_f20_60_21443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sputum from pneumococcal pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of sputum (x1000) shows abundant inflammatory cells and Gram positive diplococci; Streptococcus pneumoniae was identified from this specimen by culture and by the optochin disk test.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_60_21443=[""].join("\n");
var outline_f20_60_21443=null;
var title_f20_60_21444="Expectant management of ectopic pregnancy";
var content_f20_60_21444=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Expectant management of ectopic pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/60/21444/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/60/21444/contributors\">",
"     Togas Tulandi, MD, MHCM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/60/21444/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/60/21444/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/60/21444/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/60/21444/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/60/21444/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectopic pregnancy is a gynecologic emergency, generally requiring expeditious surgical or medical treatment. However, in a small number of cases in which the risk of tubal rupture is minimal, expectant management is appropriate. Women who are candidates for expectant management of ectopic pregnancy require informed consent about the risks of this strategy and close observation until the pregnancy has resolved.",
"   </p>",
"   <p>",
"    In a historic study, expectant management versus surgery in women with ectopic pregnancy, regardless of risk factors for tubal rupture, resulted in a 57 percent success rate [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21444/abstract/1\">",
"     1",
"    </a>",
"    ]. However, most of the patients who failed this approach had significant complications (ie, tubal rupture) or ultimately required surgery for ongoing pregnancy.",
"   </p>",
"   <p>",
"    The use of more stringent selection criteria results in an increase in the efficacy of expectant management to approximately 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21444/abstract/2\">",
"     2",
"    </a>",
"    ]. Success rates vary from 48 to 100 percent, depending in large part on differences in inclusion criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21444/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Expectant management of ectopic pregnancy will be discussed here. Medical and surgical management of ectopic pregnancy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27417?source=see_link\">",
"     \"Methotrexate treatment of tubal and interstitial ectopic pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5976?source=see_link\">",
"     \"Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16457?source=see_link\">",
"     \"Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/51/11062?source=see_link\">",
"     \"Cervical pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR EXPECTANT MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Selection criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;When ectopic pregnancy is suspected, in our practice, we employ expectant management only for patients who meet the following criteria: (1) transvaginal ultrasound (TVUS) does not show a gestational sac or demonstrate an extrauterine mass suspicious for an ectopic pregnancy and (2) the beta-human chorionic gonadotropin (hCG) concentration is low (&le;200",
"    <span class=\"nowrap\">",
"     mIU/mL)",
"    </span>",
"    and declining [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21444/abstract/4\">",
"     4",
"    </a>",
"    ]. This also the threshold advised by the American College of Obstetricians and Gynecologists (ACOG) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21444/abstract/5\">",
"     5",
"    </a>",
"    ]. We define a declining hCG level as lower at the third measurement than at the first measurement.",
"   </p>",
"   <p>",
"    Patients with no extrauterine mass on TVUS can be described as a pregnancy of unknown location since imaging and laboratory assessment do not clearly distinguish between a failed intrauterine pregnancy and a resolving ectopic pregnancy at this low level of hCG. An extrauterine mass could represent an involuting ectopic pregnancy or another type of adnexal mass. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34184?source=see_link\">",
"     \"Ultrasonography of pregnancy of unknown location\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If expectant management is offered, the patient must be aware of and accept the risks and be willing and able to comply with follow-up. As with all patients managed expectantly, such women should be treated medically or surgically if hCG levels are increasing or if there are signs of tubal rupture. We do not perform endometrial sampling in the management of ectopic pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27417?source=see_link\">",
"     \"Methotrexate treatment of tubal and interstitial ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The upper limit of serum hCG level that allows for expectant management of ectopic pregnancy without unnecessary risk of tubal rupture is unknown. Several studies have evaluated use of a hCG threshold higher than 200",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21444/abstract/4,6,7\">",
"     4,6,7",
"    </a>",
"    ]. This was best evaluated in a randomized trial (n = 73) that assigned women with an ectopic pregnancy or PUL and a plateauing hCG level to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) therapy or expectant management [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21444/abstract/7\">",
"     7",
"    </a>",
"    ]. The hCG cutoffs were &lt;1500",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    for ectopic pregnancy or &lt;2000",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    for PUL. The initial treatment was sufficient more often in women treated with MTX than expectant management (76 versus 39 percent), but this did not reach statistical significance (relative risk 1.3, 95% CI 0.9-1.8). In the expectant management group, 28 percent of women were subsequently treated with MTX. Surgery was required in 1 of 41 women (2 percent) in the MTX group and 4 of 32 (13 percent) in the expectant management group.",
"   </p>",
"   <p>",
"    In the trial cited above, a large proportion of patients assigned to expectant management ultimately required MTX and more patients required surgery, although the risk of surgery is based on few events [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21444/abstract/7\">",
"     7",
"    </a>",
"    ]. Taking into account the potentially serious risks of tubal rupture and hemorrhage with ectopic pregnancy and the safety and efficacy of medical and surgical treatment, we recommend that the more stringent hCG criterion (&le;200",
"    <span class=\"nowrap\">",
"     mIU/mL)",
"    </span>",
"    should be used for expectant management. Further study, particularly of hCG thresholds between 200 and 1500",
"    <span class=\"nowrap\">",
"     mIU/mL,",
"    </span>",
"    is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expectant treatment should not be attempted or should be abandoned in women with known or suspected ectopic pregnancy with the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemodynamically unstable",
"     </li>",
"     <li>",
"      Signs of impending or ongoing ectopic mass rupture (ie, severe or persistent abdominal pain or &gt;300 mL of free peritoneal fluid outside the pelvic cavity)",
"     </li>",
"     <li>",
"      hCG that is greater than 200",
"      <span class=\"nowrap\">",
"       mIU/mL,",
"      </span>",
"      is increasing, or is not declining",
"     </li>",
"     <li>",
"      Unwilling or unable to comply with monitoring",
"     </li>",
"     <li>",
"      Does not have timely access to a medical institution",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Success rates for expectant management of ectopic pregnancy of 48 to 100 percent have been reported. The wide variation is due, in part, to differences in inclusion criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21444/abstract/2-4,8,9\">",
"     2-4,8,9",
"    </a>",
"    ]. Expectant management appears reasonable in selected patients based upon the following data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the only randomized trial to evaluate expectant management, 60 women with ectopic pregnancy were assigned to placebo or oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (2.5 mg for five days) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21444/abstract/4\">",
"       4",
"      </a>",
"      ]. Ectopic pregnancy was diagnosed based on a positive serum hCG and TVUS finding of an adnexal mass or gestational sac with no evidence of an intrauterine pregnancy. Exclusion criteria were: adnexal mass &ge;4 cm, serum hCG rise &ge;50 percent in two days, moderate or severe abdominal pain, and signs of intraabdominal bleeding. Mean hCG levels did not differ significantly between groups; in the placebo group, the mean hCG was 211",
"      <span class=\"nowrap\">",
"       mIUm/L",
"      </span>",
"      (range 30 to 1343). Ultrasound findings were not reported. In both groups, 77 percent of patients recovered without the need for laparoscopy. The time from start of treatment to reaching an undetectable hCG level was similar for both groups, 24 days in the placebo group and 27 days in the methotrexate group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One limitation of this trial is that there is no evidence to support the efficacy of low dose oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    in treatment of ectopic pregnancy; thus, it is not surprising that both groups had similar outcomes. In addition, success rates with standard therapies (eg, intramuscular methotrexate, laparoscopy) are higher than 77 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27417?source=see_link\">",
"     \"Methotrexate treatment of tubal and interstitial ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A review of 10 studies including 347 patients that prospectively evaluated expectant management in selected patients found an overall efficacy of approximately 70 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21444/abstract/2\">",
"       2",
"      </a>",
"      ]. The diagnosis of ectopic pregnancy was not always confirmed by TVUS or laparoscopy. All patients were hemodynamically stable and had decreasing serum hCG levels. However, other variables, including size and location of the ectopic pregnancy, presence of fetal cardiac activity, the presence of symptoms, and the amount of free fluid in the pelvis, were not always specified.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients treated with expectant management should be monitored closely. Tubal rupture has been reported in women with low and declining hCG levels [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21444/abstract/10\">",
"     10",
"    </a>",
"    ]. We suggest following the hCG level every 48 hours for three measurements to confirm that it continues to decline, and then weekly until it is undetectable, at which point tubal rupture is highly unlikely. Asymptomatic women who are managed expectantly and have hCG levels that are slowly declining or have plateaued can be offered continuation of expectant management or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    injection.",
"   </p>",
"   <p>",
"    Expectant treatment should be abandoned if a patient experiences significant increase in abdominal pain, serum hCG starts to increase or fails to decrease, or a patient experiences increasing abdominal pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUBSEQUENT REPRODUCTIVE PERFORMANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subsequent hysterosalpingography has shown tubal patency of the affected tube in 93 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21444/abstract/11\">",
"     11",
"    </a>",
"    ]. Intrauterine pregnancy rates of 63 to 88 percent have been reported after expectant management of presumed ectopic pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21444/abstract/11-14\">",
"     11-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The success rate of expectant management of ectopic pregnancy is about 70 percent in women selected for a low risk of tubal rupture. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Selection criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Expectant management should only be considered by women with unknown location of their pregnancy or suspected ectopic pregnancy who have low and declining serum beta-human chorionic (hCG) levels. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Selection criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Contraindications to expectant management of ectopic pregnancy include risk factors for tubal rupture such as increasing abdominal pain, unwillingness or inability to comply with follow-up, and lack of timely access to medical care. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No studies have evaluated ultrasound criteria for successful use of expectant management in suspected ectopic pregnancy. We limit expectant management to women in whom transvaginal ultrasound does not show a gestational sac or demonstrate extrauterine mass suspicious for an ectopic pregnancy, and the hCG concentration is low (&le;200",
"      <span class=\"nowrap\">",
"       mIU/mL)",
"      </span>",
"      and declining [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21444/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Selection criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with suspected ectopic pregnancy, we recommend avoiding expectant management if the serum beta-human chorionic gonadotropin concentration is &gt;200",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We treat these women with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      or surgical therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Selection criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic women who are managed expectantly and have hCG levels that are slowly declining or have plateaued can be offered continuation of expectant management or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      injection.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21444/abstract/1\">",
"      LUND J. Early ectopic pregnancy; comments on conservative treatment. J Obstet Gynaecol Br Emp 1955; 62:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21444/abstract/2\">",
"      Yao M, Tulandi T. Current status of surgical and nonsurgical management of ectopic pregnancy. Fertil Steril 1997; 67:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21444/abstract/3\">",
"      Kirk E, Condous G, Bourne T. The non-surgical management of ectopic pregnancy. Ultrasound Obstet Gynecol 2006; 27:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21444/abstract/4\">",
"      Korhonen J, Stenman UH, Yl&ouml;stalo P. Low-dose oral methotrexate with expectant management of ectopic pregnancy. Obstet Gynecol 1996; 88:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21444/abstract/5\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 94: Medical management of ectopic pregnancy. Obstet Gynecol 2008; 111:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21444/abstract/6\">",
"      Trio D, Strobelt N, Picciolo C, et al. Prognostic factors for successful expectant management of ectopic pregnancy. Fertil Steril 1995; 63:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21444/abstract/7\">",
"      van Mello NM, Mol F, Verhoeve HR, et al. Methotrexate or expectant management in women with an ectopic pregnancy or pregnancy of unknown location and low serum hCG concentrations? A randomized comparison. Hum Reprod 2013; 28:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21444/abstract/8\">",
"      van Mello NM, Mol F, Adriaanse AH, et al. The METEX study: methotrexate versus expectant management in women with ectopic pregnancy: a randomised controlled trial. BMC Womens Health 2008; 8:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21444/abstract/9\">",
"      Banerjee S, Aslam N, Zosmer N, et al. The expectant management of women with early pregnancy of unknown location. Ultrasound Obstet Gynecol 1999; 14:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21444/abstract/10\">",
"      Tulandi T, Hemmings R, Khalifa F. Rupture of ectopic pregnancy in women with low and declining serum beta-human chorionic gonadotropin concentrations. Fertil Steril 1991; 56:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21444/abstract/11\">",
"      Rantala M, M&auml;kinen J. Tubal patency and fertility outcome after expectant management of ectopic pregnancy. Fertil Steril 1997; 68:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21444/abstract/12\">",
"      Zohav E, Gemer O, Segal S. Reproductive outcome after expectant management of ectopic pregnancy. Eur J Obstet Gynecol Reprod Biol 1996; 66:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21444/abstract/13\">",
"      Strobelt N, Mariani E, Ferrari L, et al. Fertility after ectopic pregnancy. Effects of surgery and expectant management. J Reprod Med 2000; 45:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21444/abstract/14\">",
"      Fernandez H, Lelaidier C, Baton C, et al. Return of reproductive performance after expectant management and local treatment for ectopic pregnancy. Hum Reprod 1991; 6:1474.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5455 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-C266496ECC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_60_21444=[""].join("\n");
var outline_f20_60_21444=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CANDIDATES FOR EXPECTANT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Selection criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUBSEQUENT REPRODUCTIVE PERFORMANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16457?source=related_link\">",
"      Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/51/11062?source=related_link\">",
"      Cervical pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27417?source=related_link\">",
"      Methotrexate treatment of tubal and interstitial ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/53/5976?source=related_link\">",
"      Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34184?source=related_link\">",
"      Ultrasonography of pregnancy of unknown location",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_60_21445="Measurement of adrenal androgens";
var content_f20_60_21445=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Measurement of adrenal androgens",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/60/21445/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/60/21445/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/60/21445/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/60/21445/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/60/21445/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/60/21445/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/60/21445/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which the secretion of adrenal androgens, dehydroepiandrosterone (DHEA), DHEA sulfate, and androstenedione, are regulated is unknown. The compounds themselves are largely inactive but, because they are precursors for the active androgens, testosterone and dihydrotestosterone, they are referred to as adrenal androgens. Corticotropin (ACTH) acutely stimulates the secretion of DHEA, but not DHEA sulfate. However, secretion of cortisol and adrenal androgens may be dissociated in patients with ACTH-dependent Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21445/abstract/1\">",
"     1",
"    </a>",
"    ]. Measurements of adrenal androgens in serum and urine can be helpful in the differential diagnosis of some adrenal disorders, particularly adrenal carcinoma and some forms of congenital adrenal hyperplasia and in the evaluation of hirsutism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40071?source=see_link\">",
"     \"Adrenal hyperandrogenism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SERUM DHEA AND DHEA SULFATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;DHEA and DHEA sulfate, the major adrenal 19-carbon steroids, can be measured by radioimmunoassay with or without previous extraction, as well as by liquid chromatography-mass spectrometry or chemiluminescent immunoassay [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21445/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. DHEA is by far the major product of the adrenal cortex, and over 99 percent of it is sulfated before secretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Normal values",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum DHEA concentrations range from 0.2 to 1.3",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (7 to 31",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    whereas serum DHEA sulfate concentrations range from undetectable to 470",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (12",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    in adults, depending on age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21445/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. DHEA concentrations increase about twofold and serum DHEA sulfate concentrations fall by about 75 percent by the end of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21445/abstract/5\">",
"     5",
"    </a>",
"    ]. Adrenal androgen production and therefore serum DHEA and DHEA sulfate concentrations are highest during the third decade, and decline progressively thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21445/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. In women, this decline is accompanied by a substantial fall in urinary 17-ketosteroid (17-KS) excretion (",
"    <a class=\"graphic graphic_figure graphicRef73628 \" href=\"UTD.htm?20/25/20894\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/45/20184?source=see_link\">",
"     \"Androgen production and therapy in women\"",
"    </a>",
"    .) The decline in 17-KS is much smaller in men because of the major contribution of testicular testosterone metabolites to urinary 17-KS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum DHEA concentrations exhibit a circadian rhythm that reflects the secretion of corticotropin (ACTH); they also vary during the menstrual cycle, being higher during the luteal phase. In contrast, serum DHEA sulfate concentrations do not exhibit a circadian rhythm because the plasma half-life of DHEA sulfate is much longer.",
"   </p>",
"   <p>",
"    DHEA and DHEA sulfate are derived from 17-hydroxypregnenolone and 17-hydroxyprogesterone (",
"    <a class=\"graphic graphic_figure graphicRef70372 \" href=\"UTD.htm?0/7/123\">",
"     figure 2",
"    </a>",
"    ). Their serum concentrations are, therefore, increased in conditions in which the concentration of these steroids is increased, such as the virilizing form of CYP21A2 (21-hydroxylase, P450c21) deficiency.",
"   </p>",
"   <p>",
"    Serum DHEA and DHEA sulfate concentrations can be increased in patients with some etiologies of Cushing's syndrome. They are highest in Cushing's syndrome due to androgen-secreting adrenal carcinoma and lowest in cortisol-secreting adrenal adenoma, as a consequence of ACTH suppression. In ACTH-dependent Cushing's syndrome (Cushing's disease and the ectopic ACTH syndrome), both serum DHEA and DHEA sulfate concentrations may be low-normal or only slightly elevated despite relatively elevated plasma ACTH concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21445/abstract/1\">",
"     1",
"    </a>",
"    ]. This discrepancy indicates that factors other than ACTH alone can also regulate adrenal androgen secretion.",
"   </p>",
"   <p>",
"    Other patients in whom serum DHEA and DHEA sulfate concentrations are increased include those with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Virilizing adrenal carcinoma without Cushing's syndrome, in whom the concentrations may be markedly increased.",
"     </li>",
"     <li>",
"      Congenital adrenal hyperplasias resulting from CYP11B1 (11-hydroxylase, P450c11), CYP21A2, or 3-beta-hydroxysteroid dehydrogenase deficiency, in whom adrenal androgen synthesis is intact and stimulated by the high plasma ACTH concentrations (",
"      <a class=\"graphic graphic_figure graphicRef70372 \" href=\"UTD.htm?0/7/123\">",
"       figure 2",
"      </a>",
"      ). In contrast, serum DHEA and DHEA sulfate concentrations are normal in patients with CYP11B2 (aldosterone synthase, P450c11as or P450aldo) deficiency (in which there is selective hypoaldosteronism), and low or undetectable in the CYP17 (17-hydroxylase, P450c17) and CYP11A1 (cholesterol side-chain cleavage enzyme, P450scc) deficiency forms (in which androgen synthesis is reduced). In any of the congenital adrenal hyperplasias, the degree of deviation from normal is dependent in part upon the degree of enzyme deficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=see_link\">",
"       \"Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum DHEA and DHEA sulfate levels may be reduced in patients with adrenal adenoma and mild or overt hypercortisolism because of reduced ACTH stimulation for androgen production [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21445/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SERUM TESTOSTERONE AND 4-ANDROSTENEDIONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurements of serum testosterone are of little value in assessing adrenal function in men because virtually all of it is produced by the testes. In women, however, two-thirds of the testosterone in serum is derived from the adrenal cortex, mostly via peripheral conversion of DHEA and androstenedione.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Normal values",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum testosterone concentrations range from 5 to 20",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (0.17 to 0.7",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    in prepubertal children, increase rapidly during puberty in boys to reach values of 300 to 1000",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (10 to 35",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    in men, but remain low in women (20 to 70",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    [0.7 to 2.6",
"    <span class=\"nowrap\">",
"     nmol/L]).",
"    </span>",
"    Serum androstenedione concentrations range from 160 to 200",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (5.6 to 7",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    in women and from 900 to 1400",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (3.2 to 4.7",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    in men.",
"   </p>",
"   <p>",
"    When measuring low total testosterone concentrations, the direct assays (performed without an extraction step) are unreliable and should be avoided. Assays after extraction and chromatography, followed by either mass spectrometry or immunoassay, provide reliable results and should be used in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21445/abstract/4,11\">",
"     4,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Assay technique can influence mass spectrometry results. One study comparing performance of eight assays to a reference assay found:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Different assays provide different concentration ranges. As a result, all assays are not equivalent, particularly at the lower and upper ranges.",
"     </li>",
"     <li>",
"      The reported variability for sample concentrations more than 100",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (&gt;3.47",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      was small in comparison to those of immunoassays, suggesting that mass spectrometry provides better precision at these levels.",
"     </li>",
"     <li>",
"      The variability of assays increased dramatically at low concentrations (up to 34 percent CV at 10",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      [0.3",
"      <span class=\"nowrap\">",
"       nmol/L]).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no population-based reference ranges for commercial assays. A consortium has been formed to address this. Until improved ranges are available, values close to the upper reference range may not be abnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21445/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum testosterone concentrations may be abnormal in patients with several adrenal diseases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They tend to be high in patients with the CYP11B1 and CYP21A2 deficiency forms of congenital adrenal hyperplasia, normal in patients with CYP11B2 deficiency, and low or undetectable in women with 3-beta-hydroxysteroid dehydrogenase or CYP17 deficiency. In the last two disorders, serum testosterone concentrations are also low or undetectable in men because the enzymes are missing from the testes as well as the adrenals.",
"     </li>",
"     <li>",
"      They tend to be increased in patients with Cushing's syndrome, least in adrenal adenomas and most in adrenal carcinomas; in rare carcinomas, the major hormonal product is testosterone&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21445/abstract/13\">",
"       13",
"      </a>",
"      ]. Conversely, serum testosterone concentrations are low in prepubertal children and women with primary or secondary adrenal insufficiency.",
"     </li>",
"     <li>",
"      Testosterone, androstenedione",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      DHEAS may be increased in women with androgen-producing adenomas or carcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21445/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Androstenedione is a product of 17-hydroxyprogesterone and DHEA and is the immediate precursor of testosterone. Consequently, changes in its serum concentrations tend to mirror those of testosterone.",
"   </p>",
"   <p>",
"    Dihydrotestosterone is a target tissue product of testosterone and, therefore, measurements of serum and dihydrotestosterone are of little value in assessing hypothalamic-pituitary-adrenal function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF URINARY ANDROGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;DHEA, DHEA sulfate, and testosterone can all be measured in urine by radioimmunoassay and mass spectrometry, but this is seldom done because measurements in serum usually provide the necessary clinical information. Rather, urinary 17-KS excretion is measured as an index of adrenal androgen synthesis. DHEA sulfate is the most abundant androgen and the major component of 17-KS in urine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Assay of 17-ketosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurements of 17-KS are based on formation of a pinkish-purple derivative of 17-KS with m-dinitrobenzene in the presence of alkali [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21445/abstract/15\">",
"     15",
"    </a>",
"    ]. The 17-KS consist of 19-carbon steroids, mainly DHEA and DHEA sulfate; their metabolites, including 4-androstenedione, etiocholanolone, and estrone glucuronides; and etiocholanolone sulfate. Testosterone and dihydrotestosterone, the only potent androgens, constitute less than 1 percent of total urinary 17-KS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21445/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Normal values",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary 17-KS excretion ranges from about 5 to 15 mg (17 to 52 &micro;mol) per 24 hours in women and 10 to 20 mg (34 to 69 &micro;mol) per 24 hours in men. The values tend to decline above age 30 years in women (",
"    <a class=\"graphic graphic_figure graphicRef73628 \" href=\"UTD.htm?20/25/20894\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Interpretation and usefulness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary 17-KS excretion is not as accurate an index of cortisol production as is urinary 17-hydroxycorticosteroid (17-OHCS) or cortisol excretion. Similarly, urinary 17-KS excretion is not as accurate an index of androgen production as are measurements of serum testosterone, DHEA, DHEA sulfate, and androstenedione. Because of the development of more specific assays for serum androgens, urinary 17-KS excretion is rarely measured now.",
"   </p>",
"   <p>",
"    Measurement of urinary 17-KS excretion may be helpful in the following situations. However, measurement of specific hormones may be more convenient and equally useful.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is often markedly and disproportionately high, with respect to urinary 17-OHCS or cortisol excretion, in patients with adrenal carcinoma, with or without Cushing's syndrome; this is a reflection of the patients' high serum DHEA sulfate concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21445/abstract/17\">",
"       17",
"      </a>",
"      ]. Urinary 17-KS excretion tends to be lower and may be normal in patients with an adrenal adenoma that secretes excess cortisol and causes Cushing's syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21445/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It is high in patients with congenital CYP11B1 and CYP21A2 deficiency and can be used, in conjunction with measurements of serum 17-hydroxyprogesterone, to monitor the efficacy of glucocorticoid replacement therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Various drugs interfere with the 17-KS assay, several of which also interfere with the 17-OHCS assay. Some (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    , ethinamate,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/43/19125?source=see_link\">",
"     meprobamate",
"    </a>",
"    , nalidixic acid, penicillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    , phenaglycodol, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    ) result in falsely high values, and others (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , cephalothin, glucose,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4679?source=see_link\">",
"     chlordiazepoxide",
"    </a>",
"    , progestational agents, propoxyphene, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/35/16950?source=see_link\">",
"     reserpine",
"    </a>",
"    ) result in falsely low values. As in the 17-OHCS assay, these drugs can be detected and can often be eliminated by solvent partition or chromatography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal androgens production and, therefore, serum DHEA and DHEA sulfate concentrations, are highest during the third decade and decline progressively thereafter.",
"   </p>",
"   <p>",
"    Serum DHEA concentrations exhibit a circadian rhythm that reflects the secretion of corticotropin (ACTH), while serum DHEA sulfate concentrations do not exhibit a circadian rhythm because the plasma half-life of DHEA sulfate is much longer.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As a result, serum DHEA sulfate reflects integrated production and is usually a better marker of production.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    DHEA sulfate values may be increased in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Virilizing adrenal carcinoma without Cushing's syndrome",
"     </li>",
"     <li>",
"      Congenital adrenal hyperplasias resulting from CYP11B1 (11-hydroxylase, P450c11), CYP21A2, or 3-beta-hydroxysteroid dehydrogenase deficiency, in whom adrenal androgen synthesis is intact and stimulated by the high plasma ACTH concentrations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum DHEA and DHEA sulfate concentrations are normal in patients with CYP11B2 (aldosterone synthase, P450c11as or P450aldo), and low or undetectable in the CYP17 (17-hydroxylase, P450c17) and CYP11A1 (cholesterol side-chain cleavage enzyme, P450scc) deficiency forms. In any of the congenital adrenal hyperplasias, the degree of deviation from normal is dependent in part upon the degree of enzyme deficiency.",
"   </p>",
"   <p>",
"    Serum DHEA and DHEAS concentrations may be decreased in patients with adrenal adenoma and ACTH-independent Cushing's syndrome, because of reduced ACTH stimulation, and in women with primary or secondary adrenal insufficiency.",
"   </p>",
"   <p>",
"    Measurements of serum testosterone are of little value in assessing adrenal function in men because the testes produce nearly all of it. In women, however, two-thirds of the testosterone in serum is derived from the adrenal cortex, mostly via peripheral conversion of DHEA and androstenedione.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In women, testosterone is increased in those with the CYP11B1 and CYP21A2 deficiency forms of congenital adrenal hyperplasia, and patients with androgen-secreting adrenal carcinomas.",
"     </li>",
"     <li>",
"      Testosterone is normal in patients with CYP11B2 deficiency.",
"     </li>",
"     <li>",
"      Testosterone concentrations are low or undetectable in men and women with 3-beta-hydroxysteroid dehydrogenase or CYP17 deficiency. In the last two disorders, serum testosterone concentrations are also low or undetectable in men because the enzymes are missing from the testes, as well as the adrenals.",
"     </li>",
"     <li>",
"      Serum testosterone concentrations are low in prepubertal children and women with primary or secondary adrenal insufficiency, and in women with adrenal adenoma and hypercortisolism.",
"     </li>",
"     <li>",
"      In general, serum androstenedione changes parallel those of testosterone.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21445/abstract/1\">",
"      Cunningham SK, McKenna TJ. Dissociation of adrenal androgen and cortisol secretion in Cushing's syndrome. Clin Endocrinol (Oxf) 1994; 41:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21445/abstract/2\">",
"      Yamaji T, Ishibashi M, Takaku F, et al. Serum dehydroepiandrosterone sulfate concentrations in secondary adrenal insufficiency. J Clin Endocrinol Metab 1987; 65:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21445/abstract/3\">",
"      Chadwick CA, Owen LJ, Keevil BG. Development of a method for the measurement of dehydroepiandrosterone sulphate by liquid chromatography-tandem mass spectrometry. Ann Clin Biochem 2005; 42:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21445/abstract/4\">",
"      Dorgan JF, Fears TR, McMahon RP, et al. Measurement of steroid sex hormones in serum: a comparison of radioimmunoassay and mass spectrometry. Steroids 2002; 67:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21445/abstract/5\">",
"      Tulchinsky D, Simmer HH. Sources of plasma 17alpha-hydroxyprogesterone in human pregnancy. J Clin Endocrinol Metab 1972; 35:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21445/abstract/6\">",
"      Thomas G, Frenoy N, Legrain S, et al. Serum dehydroepiandrosterone sulfate levels as an individual marker. J Clin Endocrinol Metab 1994; 79:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21445/abstract/7\">",
"      Ravaglia G, Forti P, Maioli F, et al. The relationship of dehydroepiandrosterone sulfate (DHEAS) to endocrine-metabolic parameters and functional status in the oldest-old. Results from an Italian study on healthy free-living over-ninety-year-olds. J Clin Endocrinol Metab 1996; 81:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21445/abstract/8\">",
"      Labrie F, B&eacute;langer A, Cusan L, et al. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 1997; 82:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21445/abstract/9\">",
"      Nestler JE, Whitfield JB, Williams TY, et al. Genetics of serum dehydroepiandrosterone sulfate and its relationship to insulin in a population-based cohort of twin subjects. J Clin Endocrinol Metab 2002; 87:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21445/abstract/10\">",
"      Flecchia D, Mazza E, Carlini M, et al. Reduced serum levels of dehydroepiandrosterone sulphate in adrenal incidentalomas: a marker of adrenocortical tumour. Clin Endocrinol (Oxf) 1995; 42:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21445/abstract/11\">",
"      Rosner W, Auchus RJ, Azziz R, et al. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007; 92:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21445/abstract/12\">",
"      Bhasin S, Zhang A, Coviello A, et al. The impact of assay quality and reference ranges on clinical decision making in the diagnosis of androgen disorders. Steroids 2008; 73:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21445/abstract/13\">",
"      Burr IM, Graham T, Sullivan J, et al. A testosterone-secreting tumour of the adrenal producing virilisation in a female infant. Lancet 1973; 2:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21445/abstract/14\">",
"      Kaltsas GA, Isidori AM, Kola BP, et al. The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. J Clin Endocrinol Metab 2003; 88:2634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21445/abstract/15\">",
"      Zimmerman, W. Eine Farbreaktion der Sexualhormone und ihre Anwendung zur quantitativen colorimetrischen Bestimmung. Hoppe Seylers Z. Physiol Chem 1935; 233:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21445/abstract/16\">",
"      Maroulis GB, Manlimos FS, Abraham GE. Comparison between urinary 17-ketosteroids and serum androgens in hirsute patients. Obstet Gynecol 1977; 49:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21445/abstract/17\">",
"      Yamaji T, Ishibashi M, Sekihara H, et al. Serum dehydroepiandrosterone sulfate in Cushing's syndrome. J Clin Endocrinol Metab 1984; 59:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21445/abstract/18\">",
"      Bertagna C, Orth DN. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med 1981; 71:855.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 168 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-75239E8C8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_60_21445=[""].join("\n");
var outline_f20_60_21445=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SERUM DHEA AND DHEA SULFATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Normal values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SERUM TESTOSTERONE AND 4-ANDROSTENEDIONE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Normal values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MEASUREMENT OF URINARY ANDROGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Assay of 17-ketosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Normal values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Interpretation and usefulness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/168\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/168|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/25/20894\" title=\"figure 1\">",
"      Adrenal androgens and age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/7/123\" title=\"figure 2\">",
"      Adrenal steroid synthesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40071?source=related_link\">",
"      Adrenal hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/45/20184?source=related_link\">",
"      Androgen production and therapy in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=related_link\">",
"      Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_60_21446="Prediction of variceal hemorrhage in patients with cirrhosis";
var content_f20_60_21446=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prediction of variceal hemorrhage in patients with cirrhosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/60/21446/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/60/21446/contributors\">",
"     Arun J Sanyal, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/60/21446/contributors\">",
"     Jasmohan S Bajaj, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/60/21446/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/60/21446/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/60/21446/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/60/21446/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/60/21446/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H129709511\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cirrhosis affects 3.6 out of every 1000 adults in North America, and is responsible for over one million days of work loss and 32,000 deaths annually. A major cause of cirrhosis-related morbidity and mortality is the development of variceal hemorrhage, a direct consequence of portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21446/abstract/1\">",
"     1",
"    </a>",
"    ]. Each episode of active variceal hemorrhage is associated with 30 percent mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21446/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In addition, survivors of an episode of active bleeding have a 70 percent risk of recurrent hemorrhage within one year of the bleeding episode [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21446/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variceal hemorrhage occurs in 25 to 40 percent of patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21446/abstract/5\">",
"     5",
"    </a>",
"    ]. While several modalities are available for primary prophylaxis of variceal bleeding, many are associated with significant adverse effects.",
"   </p>",
"   <p>",
"    Accurate identification of patients at highest risk of bleeding permits stratification in an attempt to avoid potentially harmful preventive treatments in the 60 to 75 percent of patients who will never have variceal bleeding.",
"   </p>",
"   <p>",
"    This topic will review the formation and progression of varices and the predictive factors and risk classification for variceal bleeding. Primary prophylaxis for variceal hemorrhage, the treatment of variceal hemorrhage, and the prevention of recurrent variceal hemorrhage in patients with cirrhosis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=see_link\">",
"     \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1928?source=see_link\">",
"     \"General principles of the management of variceal hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17786?source=see_link\">",
"     \"Prevention of recurrent variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H129709519\">",
"    <span class=\"h1\">",
"     FORMATION OF VARICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Portal pressure is determined by the product of portal flow volume and resistance to outflow from the portal vein. Portal hypertension (defined as hydrostatic pressure &gt;5 mmHg) results initially from obstruction to portal venous outflow. Obstruction may occur at a presinusoidal (portal vein thrombosis, portal fibrosis, or infiltrative lesions), sinusoidal (cirrhosis), or postsinusoidal (veno-occlusive disease, Budd Chiari syndrome) level. Cirrhosis is the most common cause of portal hypertension; in these patients, elevated portal pressure results from both increased resistance to outflow through distorted hepatic sinusoids, and enhanced portal inflow due to splanchnic arteriolar vasodilation.",
"   </p>",
"   <p>",
"    Varices develop in order to decompress the hypertensive portal vein and return blood to the systemic circulation. They are seen when the pressure gradient between the portal and hepatic veins rises above 12 mmHg; patients with lower values do not form varices and do not bleed. The portal-hepatic venous pressure gradient is obtained by hepatic venous catheterization, with measurement of the difference between the wedged hepatic venous pressure (which approximates the sinusoidal and portal pressures in cirrhosis) and the free hepatic venous pressure. This procedure is routinely performed in many European centers, but less commonly in the United States. Although it does not predict the size of varices, it may be useful for monitoring the success of therapy aimed at lowering portal pressures, such as beta blockers. A systematic review of 12 studies found that a reduction of the hepatic vein pressure gradient to less than or equal to 12 mmHg was associated with a significant reduction in the risk of variceal bleeding and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21446/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An illustrative study evaluated the relationship between the hepatic vein pressure gradient and the formation of and bleeding from varices [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21446/abstract/7\">",
"     7",
"    </a>",
"    ]. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All 72 patients with varices by endoscopy had a gradient above 12 mmHg",
"     </li>",
"     <li>",
"      The mean gradient in 49 patients with bleeding varices was 20.4 mmHg and none of these patients had a gradient below 12 mmHg",
"     </li>",
"     <li>",
"      The gradient did not predict the size of varices, being similar in those with large and small varices",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H129709527\">",
"    <span class=\"h1\">",
"     PROGRESSION OF VARICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of development and progression of esophageal varices in patients with cirrhosis has not been extensively evaluated. One of the largest prospective studies included 206 cirrhotic patients (113 without varices and 93 with small esophageal varices at baseline) who were followed prospectively for an average of 37 months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21446/abstract/8\">",
"     8",
"    </a>",
"    ]. An endoscopy was performed annually. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      New varices developed in 5 percent at year one, and 28 percent at year three",
"     </li>",
"     <li>",
"      Small varices progressed in size at a rate of 12 percent in year one, and 31 percent at year three",
"     </li>",
"     <li>",
"      Progression was predicted by the Child-Pugh score (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?27/26/28065?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?28/28/29121?source=see_link\">",
"       calculator 2",
"      </a>",
"      ), the presence of red wale marks on the first examination, and an alcoholic cause of cirrhosis",
"     </li>",
"     <li>",
"      The two-year risk of bleeding was significantly higher in patients with small varices at enrollment compared with those without varices (12 versus 2 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar study in patients with Child class A cirrhosis due to chronic hepatitis C showed that over 12 years of follow-up, none of the patients who achieved a sustained virological response (SVR) developed varices compared with 32 percent of untreated patients, and 39 percent of treated patients who did not attain an SVR [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21446/abstract/9\">",
"     9",
"    </a>",
"    ]. The rate of variceal development was related to HCV genotype 1b and to baseline MELD score (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=see_link\">",
"     calculator 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=see_link\">",
"     \"Model for End-stage Liver Disease (MELD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When patients with primary sclerosing cholangitis (PSC) were followed over five years, 20 percent were found to have de novo esophageal varices. A higher baseline Mayo clinical risk score and",
"    <span class=\"nowrap\">",
"     AST/ALT",
"    </span>",
"    ratio was associated with varices, while the development of varices was associated with a platelet count less than 204 and a bilirubin greater than 1.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21446/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H129709535\">",
"    <span class=\"h1\">",
"     PREDICTIVE FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous clinical and physiologic factors are useful in predicting the risk of variceal hemorrhage in patients with cirrhosis. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Location of varices",
"     </li>",
"     <li>",
"      Size of varices",
"     </li>",
"     <li>",
"      Appearance of varices",
"     </li>",
"     <li>",
"      Clinical features of the patient",
"     </li>",
"     <li>",
"      Variceal pressure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H129709543\">",
"    <span class=\"h2\">",
"     Location of varices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common sites for development of varices are the distal esophagus, stomach, and rectum, although theoretically varices may develop at any level of the gastrointestinal (GI) tract between the esophagus and rectum. Varices develop deep within the submucosa in the mid-esophagus, but become progressively more superficial in the distal esophagus. Thus, esophageal varices at the gastroesophageal junction have the thinnest layer of supporting tissue and are most likely to rupture and bleed.",
"   </p>",
"   <p>",
"    Varices in the gastric fundus also bleed frequently. Gastric varices are often classified according to their location, which correlates with their risk of hemorrhage:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Varices in direct continuity with the esophagus along the lesser and greater curvatures of the stomach are called gastroesophageal varices (GOV) types 1 and 2 respectively.",
"     </li>",
"     <li>",
"      Isolated gastric varices in the fundus (IGV1) occur less frequently than GOVs (10 versus 90 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21446/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relationship between the site of the varices and the clinical risk of bleeding was illustrated in a prospective study of 568 consecutive patients with varices, 393 of whom were bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21446/abstract/11\">",
"     11",
"    </a>",
"    ]. The mean transfusion requirement in patients with bleeding gastric varices was higher than in those with esophageal varices (4.8 versus 2.9 units per patient). Bleeding from isolated gastric varices in the fundus (IGV1) occurred much more frequently than either GOVs or isolated gastric varices at other loci in the stomach (IGV2) (",
"    <a class=\"graphic graphic_figure graphicRef55976 \" href=\"UTD.htm?1/29/1502\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H129709551\">",
"    <span class=\"h2\">",
"     Size of varices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of variceal bleeding correlates independently with the diameter (size) of the varix. The explanation for the relationship between variceal size and bleeding risk is derived from Laplace's law; small increases in the vessel radius result in a large increase in wall tension (which is the force tending to cause variceal rupture).",
"   </p>",
"   <p>",
"    There are several ways in which esophageal variceal size is quantified; none are exact and all involve subjective evaluation. A commonly employed system of classification includes the following (",
"    <a class=\"graphic graphic_picture graphicRef61770 \" href=\"UTD.htm?42/51/43838\">",
"     picture 1",
"    </a>",
"    )[",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21446/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      F1: Small, straight varices",
"     </li>",
"     <li>",
"      F2: Enlarged, tortuous varices that occupy less than one-third of the lumen",
"     </li>",
"     <li>",
"      F3: Large, coil-shaped varices that occupy more than one-third of the lumen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to insufflate the esophagus while estimating variceal size, as failure to do so leads to overestimation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H129709559\">",
"    <span class=\"h2\">",
"     Appearance of varices",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to size, several morphologic features of varices observed at endoscopy have been correlated with an increased risk of hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21446/abstract/8,11,14\">",
"     8,11,14",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Among these features include a number relating to a red appearance, or \"red signs\":",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Red wale marks are longitudinal red streaks on varices that resemble red corduroy wales (",
"      <a class=\"graphic graphic_picture graphicRef50222 \" href=\"UTD.htm?7/25/7568\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cherry red spots are discrete red cherry-colored spots that are flat and overlie varices.",
"     </li>",
"     <li>",
"      Hematocystic spots are raised discrete red spots overlying varices that resemble \"blood blisters\".",
"     </li>",
"     <li>",
"      Diffuse erythema denotes a diffuse red color of the varix.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H129709567\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several clinical features of the patient are related to the risk of variceal hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21446/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The degree of liver dysfunction is an important predictor of variceal hemorrhage. The Child classification is an index of liver dysfunction based upon serum albumin concentration, bilirubin level, prothrombin time, and the presence of ascites and encephalopathy (",
"      <a class=\"graphic graphic_table graphicRef78401 \" href=\"UTD.htm?8/21/8540\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?27/26/28065?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?28/28/29121?source=see_link\">",
"       calculator 2",
"      </a>",
"      ). A higher score in this classification scheme is associated with a higher likelihood of variceal bleeding.",
"     </li>",
"     <li>",
"      History of a previous variceal bleed predicts a high likelihood of a subsequent bleeding episode. As an example, while only one-third of all patients with cirrhosis experience variceal hemorrhage, over 70 percent experience further episodes of variceal bleeding after an index bleed. These bleeding episodes may be considered as \"early\" or \"late\" with respect to their temporal relationship to the index bleed; one-third of patients with an index bleed will rebleed within six weeks, and one-third will rebleed after six weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21446/abstract/4\">",
"       4",
"      </a>",
"      ]. The risk of early rebleeding is greatest in the first 48 hours after admission and declines subsequently.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk factors for early and late rebleeding are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef52618 \" href=\"UTD.htm?0/10/171\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21446/abstract/13,15,16\">",
"     13,15,16",
"    </a>",
"    ]. The risk of early rebleeding is greatest immediately after cessation of active hemorrhage (50 percent of such episodes occur within 48 hours) and subsides over time.",
"   </p>",
"   <p>",
"    There is evidence that treatment of the underlying cause of the liver disease may reduce the severity of the portal hypertension and subsequent variceal hemorrhage. This is most often seen in patients who start alcohol abstinence and in those who have achieved a sustained virological response after hepatitis C therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21446/abstract/1,9,17\">",
"     1,9,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H129709575\">",
"    <span class=\"h2\">",
"     Variceal pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variceal pressure may be measured accurately and relatively noninvasively with a pressure-sensitive endoscopic gauge, though this is not routinely done [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21446/abstract/18\">",
"     18",
"    </a>",
"    ]. The variceal pressure may be an important predictor for variceal hemorrhage. In one study, for example, 87 patients with cirrhosis and large esophageal varices who had never had variceal bleeding were followed for 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21446/abstract/19\">",
"     19",
"    </a>",
"    ]. Variceal hemorrhage developed in 28 patients (32 percent). Variables predictive of a first bleed included: the level of variceal pressure; risk classification using the Child class, variceal size, and endoscopic appearance of the varices (see below); and the interval between diagnosis of varices and the start of the study. Specifically, the incidence of variceal bleeding with different levels of variceal pressure was as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &le;13 mmHg -",
"      <span class=\"nowrap\">",
"       0/25",
"      </span>",
"      (0 percent)",
"     </li>",
"     <li>",
"      &gt;13 and &le;14 mmHg -",
"      <span class=\"nowrap\">",
"       1/11",
"      </span>",
"      (9 percent)",
"     </li>",
"     <li>",
"      &gt;14 and &le;15 mmHg -",
"      <span class=\"nowrap\">",
"       2/12",
"      </span>",
"      (17 percent)",
"     </li>",
"     <li>",
"      &gt;15 and &le;16 mmHg -",
"      <span class=\"nowrap\">",
"       7/14",
"      </span>",
"      (50 percent)",
"     </li>",
"     <li>",
"      &gt;16 mmHg -",
"      <span class=\"nowrap\">",
"       18/25",
"      </span>",
"      (72 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adding variceal pressure (categorized as &gt; or &le;15.2 mmHg) to the risk classification discussed below significantly improved the predictive value of this classification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H129709583\">",
"    <span class=\"h1\">",
"     RISK CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Child class (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?27/26/28065?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?28/28/29121?source=see_link\">",
"     calculator 2",
"    </a>",
"    ), variceal size, and presence of red wale markings can be used to calculate a prognostic index that numerically quantifies the risk of variceal hemorrhage in an individual patient (",
"    <a class=\"graphic graphic_table graphicRef65361 \" href=\"UTD.htm?19/18/19756\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21446/abstract/12\">",
"     12",
"    </a>",
"    ]. The calculated risk is greatest in the first one to two years from the time of identification of these risk factors. As an example, a patient with Child class C cirrhosis and tense ascites who has large varices with red signs has an approximately 76 percent likelihood of developing variceal hemorrhage within one year. Such a patient is clearly a candidate for prophylactic therapy to prevent bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=see_link\">",
"     \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study evaluated variables that predicted the presence of high risk varices (ie, medium to large varices) in 1000 patients with HCV who had advanced fibrosis but compensated liver function [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21446/abstract/20\">",
"     20",
"    </a>",
"    ]. Such varices were rare in those with a platelet count over 150,000 (negative predictive value of 99 percent). Whether these data can be generalized to other forms of liver disease is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/9/12434?source=see_link\">",
"       \"Patient information: Screening for esophageal varices (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H129709599\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Variceal hemorrhage occurs in 25 to 40 percent of patients with cirrhosis. Accurate identification of patients at highest risk of bleeding permits targeted use of preventive measures.",
"     </li>",
"     <li>",
"      Numerous clinical and physiologic factors are useful in predicting the risk of variceal hemorrhage in patients with cirrhosis. These include the location, size and appearance of varices, their pressure, and clinical features of the patient. (See",
"      <a class=\"local\" href=\"#H129709535\">",
"       'Predictive factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      These factors can be considered together to help predict the risk of hemorrhage in an individual patient (",
"      <a class=\"graphic graphic_table graphicRef65361 \" href=\"UTD.htm?19/18/19756\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H129709583\">",
"       'Risk classification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21446/abstract/1\">",
"      Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010; 362:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21446/abstract/2\">",
"      Smith JL, Graham DY. Variceal hemorrhage: a critical evaluation of survival analysis. Gastroenterology 1982; 82:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21446/abstract/3\">",
"      DeDombal FT, Clarke JR, Clamp SE, et al. Prognostic factors in upper GI bleeding. Endoscopy 1986; 18:6s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21446/abstract/4\">",
"      Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981; 80:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21446/abstract/5\">",
"      Grace ND. Prevention of initial variceal hemorrhage. Gastroenterol Clin North Am 1992; 21:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21446/abstract/6\">",
"      D'Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006; 131:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21446/abstract/7\">",
"      Garcia-Tsao G, Groszmann RJ, Fisher RL, et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985; 5:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21446/abstract/8\">",
"      Merli M, Nicolini G, Angeloni S, et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol 2003; 38:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21446/abstract/9\">",
"      Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010; 51:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21446/abstract/10\">",
"      Treeprasertsuk S, Kowdley KV, Luketic VA, et al. The predictors of the presence of varices in patients with primary sclerosing cholangitis. Hepatology 2010; 51:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21446/abstract/11\">",
"      Sarin SK, Lahoti D, Saxena SP, et al. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology 1992; 16:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21446/abstract/12\">",
"      North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med 1988; 319:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21446/abstract/13\">",
"      Beppu K, Inokuchi K, Koyanagi N, et al. Prediction of variceal hemorrhage by esophageal endoscopy. Gastrointest Endosc 1981; 27:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21446/abstract/14\">",
"      Kim T, Shijo H, Kokawa H, et al. Risk factors for hemorrhage from gastric fundal varices. Hepatology 1997; 25:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21446/abstract/15\">",
"      de Franchis R, Primignani M. Why do varices bleed? Gastroenterol Clin North Am 1992; 21:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21446/abstract/16\">",
"      D'Amico G, Morabito A, Pagliaro L. Six week prognostic indicators in upper gastrointestinal hemorrhage in cirrhotics. Front Gastrointest Res 1986; 9:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21446/abstract/17\">",
"      Singal AG, Volk ML, Jensen D, et al. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21446/abstract/18\">",
"      Bosch J, Bordas JM, Rigau J, et al. Noninvasive measurement of the pressure of esophageal varices using an endoscopic gauge: comparison with measurements by variceal puncture in patients undergoing endoscopic sclerotherapy. Hepatology 1986; 6:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21446/abstract/19\">",
"      Nevens F, Bustami R, Scheys I, et al. Variceal pressure is a factor predicting the risk of a first variceal bleeding: a prospective cohort study in cirrhotic patients. Hepatology 1998; 27:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21446/abstract/20\">",
"      Sanyal AJ, Fontana RJ, Di Bisceglie AM, et al. The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc 2006; 64:855.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1244 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-67CE5B8581-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_60_21446=[""].join("\n");
var outline_f20_60_21446=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H129709599\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H129709511\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H129709519\">",
"      FORMATION OF VARICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H129709527\">",
"      PROGRESSION OF VARICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H129709535\">",
"      PREDICTIVE FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H129709543\">",
"      Location of varices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H129709551\">",
"      Size of varices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H129709559\">",
"      Appearance of varices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H129709567\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H129709575\">",
"      Variceal pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H129709583\">",
"      RISK CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H129709599\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1244\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1244|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/29/1502\" title=\"figure 1\">",
"      Bleeding risk gastric varices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1244|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/51/43838\" title=\"picture 1\">",
"      Size classification of varices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/25/7568\" title=\"picture 2\">",
"      Red wale Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1244|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/21/8540\" title=\"table 1\">",
"      Child Pugh classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/10/171\" title=\"table 2\">",
"      Risk recurrent variceal bleed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/18/19756\" title=\"table 3\">",
"      Probability bleeding varices",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?27/26/28065?source=related_link\" title=\"calculator 1\">",
"      Calculator: Child Pugh classification for severity of liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?28/28/29121?source=related_link\" title=\"calculator 2\">",
"      Calculator: Child Pugh classification for severity of liver disease (SI units)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=related_link\" title=\"calculator 3\">",
"      Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/56/1928?source=related_link\">",
"      General principles of the management of variceal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/9/12434?source=related_link\">",
"      Patient information: Screening for esophageal varices (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17786?source=related_link\">",
"      Prevention of recurrent variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=related_link\">",
"      Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_60_21447="Islets of Langerhans";
var content_f20_60_21447=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F80502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F80502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Islets of Langerhans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 400px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the anatomic relationships in an islet of Langerhans. The insulin-producing &Beta; cells (in blue) are in the center closest to the blood supply and are surrounded by the glucagon-producing alpha (&alpha;) cells (in orange). On the outside are the delta (&delta;) cells (in yellow), which make somatostatin, and the PP cells (in green), which make pancreatic polypeptide.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_60_21447=[""].join("\n");
var outline_f20_60_21447=null;
var title_f20_60_21448="Topiramate: Pediatric drug information";
var content_f20_60_21448=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"18\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Topiramate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"    see \"Topiramate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/31/8694?source=see_link\">",
"    see \"Topiramate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F229206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Topamax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F229207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Topiramate&reg;;",
"     </li>",
"     <li>",
"      CO Topiramate;",
"     </li>",
"     <li>",
"      Dom-Topiramate;",
"     </li>",
"     <li>",
"      Mint-Topiramate;",
"     </li>",
"     <li>",
"      Mylan-Topiramate;",
"     </li>",
"     <li>",
"      Novo-Topiramate;",
"     </li>",
"     <li>",
"      PHL-Topiramate;",
"     </li>",
"     <li>",
"      PMS-Topiramate;",
"     </li>",
"     <li>",
"      PRO-Topiramate;",
"     </li>",
"     <li>",
"      ratio-Topiramate;",
"     </li>",
"     <li>",
"      Sandoz-Topiramate;",
"     </li>",
"     <li>",
"      Topamax&reg;;",
"     </li>",
"     <li>",
"      ZYM-Topiramate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12675768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Neuroprotectant following anoxic injury (with cooling):",
"     </b>",
"     Full-term: Limited data available; efficacy not established, results variable: 5 mg/kg/dose on day 1 followed by 3 mg/kg/dose once daily on day 2 and 3 was used in 11 neonates in study of safety; no adverse effects were noted (Filippi, 2010).  In an earlier pharmacokinetic pilot study of 13 neonates, the same investigators used 5 mg/kg/dose once daily for 3 days; results showed targeted serum concentrations (5-20 ng/mL) were achieved in 11 or 13 patients with some accumulation in patients treated with deep hypothermia (Filippi, 2009). Further studies are needed.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"      see \"Topiramate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anticonvulsant, adjunctive therapy:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-16 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Partial onset seizures or Lennox-Gastaut syndrome: Initial: 1-3 mg/kg/day (maximum: 25 mg) given nightly for 1 week; increase at 1- to 2-week intervals by 1-3 mg/kg/day given in 2 divided doses; titrate dose to response; usual maintenance: 5-9 mg/kg/day given in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Primary generalized tonic-clonic seizures: Use initial dose as listed above, but use slower initial titration rate; titrate to 6 mg/kg/day by the end of 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents &ge;17 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Partial onset seizures: Initial: 25-50 mg/day given daily for 1 week; increase at weekly intervals by 25-50 mg/day; give in 2 divided doses; titrate dose to response; usual maintenance: 100-200 mg twice daily; maximum dose: 1600 mg/day;",
"     <b>",
"      Note:",
"     </b>",
"     Doses above 400 mg/day have not been shown to increase efficacy in dose-response studies in adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Primary generalized tonic-clonic seizures: Use initial dose as listed above, but use slower initial titration rate; give in 2 divided doses; titrate upwards to recommended dose by the end of 8 weeks; usual maintenance: 200 mg twice daily; maximum dose: 1600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anticonvulsant, monotherapy: Partial onset seizures or primary generalized tonic-clonic seizures:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2 to &lt;10 years: Initial: 25 mg once daily (in evening); may increase if tolerated to 25 mg twice daily in week 2; thereafter, may increase by 25-50 mg/day at weekly intervals over 5-7 weeks up to the lower end of the target daily maintenance dosing range (ie, to the minimum recommended maintenance dose); if additional seizure control is needed and therapy is tolerated, may further increase by 25-50 mg/day at weekly intervals up to the upper end of the target daily maintenance dosing range (ie, to the maximum recommended maintenance dose):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Target daily maintenance dosing range:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &le;11 kg: 150-250 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     12-22 kg: 200-300 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     23-31 kg: 200-350 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     32-38 kg: 250-350 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;38 kg: 250-400 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;10 years and Adults: Initial: 25 mg twice daily; increase at weekly intervals by 50 mg/day up to a dose of 100 mg twice daily (week 4 dose); thereafter, may further increase at weekly intervals by 100 mg/day up to the recommended maximum dose of 200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Migraine prophylaxis:",
"     </b>",
"     Adults: Initial: 25 mg/day; increase at weekly intervals by 25 mg/day; give in 2 divided doses; titrate dose to response; recommended dose: 50 mg twice daily;",
"     <b>",
"      Note:",
"     </b>",
"     A randomized controlled trial that included adolescent patients, titrated doses based on response, up to a maximum dose of 100 mg twice daily (Brandes, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;70 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 50% of the usual dose; titrate more slowly due to prolonged half-life; supplemental doses may be required in patients undergoing hemodialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Carefully adjust dose as plasma concentrations may be increased if normal dosing is used",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F229180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, sprinkle, oral: 15 mg, 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Topamax&reg;: 15 mg, 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 50 mg, 100 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Topamax&reg;: 25 mg, 50 mg, 100 mg, 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F229165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM152837.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM152837.pdf,",
"     </a>",
"     must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to food; broken tablets have a bitter taste; tablets may be crushed, mixed with water, and administered immediately. Swallow sprinkle capsules whole or open and sprinkle contents on small amount of soft food (eg, 1 teaspoonful of applesauce, oatmeal, ice cream, pudding, custard, or yogurt); swallow sprinkle/food mixture immediately; do not chew; do not store for later use; drink fluids after dose to make sure mixture is completely swallowed",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1055786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect from moisture; store at room temperature",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial monotherapy of primary generalized tonic-clonic seizures or partial onset seizures (FDA approved in ages &ge;2 years and adults); adjunctive treatment of primary generalized tonic-clonic seizures or partial onset seizures (FDA approved in ages &ge;2 years and adults); adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (FDA approved in ages &ge;2 years); prophylaxis of migraine headache (FDA approved in adults); may potentially be useful in infantile spasms",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F229250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Topamax&reg; may be confused with Sporanox&reg;, TEGretol&reg;, TEGretol&reg;-XR, Toprol-XL&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F229248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, chest pain, edema, hypertension, pallor, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal coordination, aggressive reactions, agitation, anxiety, apathy, ataxia, behavior problems, confusion, cognitive problems, depression, difficulty concentrating, dizziness, emotional lability, fatigue, fever, hallucination, hypoesthesia, insomnia, memory difficulties, mood problems, neurosis, nervousness, psychomotor slowing, psychosis, seizure, speech problems, somnolence, stupor, suicide attempt, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, dermatitis, eczema, hypertrichosis, pruritus, seborrhea, skin discoloration, skin disorder, rash erythematous",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain, hot flashes, hypoglycemia, libido decreased, menstrual irregularities, metabolic acidosis (hyperchloremia, nonanion gap), serum bicarbonate decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, appetite increased, constipation, diarrhea, dysgeusia, dyspepsia, dysphagia, fecal incontinence, flatulence, gastroenteritis, GERD, gingivitis, glossitis, gum hyperplasia, loss of taste, nausea, salivation increased, vomiting, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Cystitis, impotence, incontinence, leukorrhea, nocturia, premature ejaculation, UTI",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, hematoma, leukopenia, purpura, prothrombin time increased, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, gait abnormal, hyperkinesia, hyporeflexia, involuntary muscle contractions, leg cramps, leg pain, myalgia, paresthesia, rigors, skeletal pain, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Abnormal vision, diplopia, conjunctivitis, lacrimation abnormal, myopia, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing decreased, otitis media, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hematuria, renal calculus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough, dyspnea, epistaxis, pharyngitis, pneumonia, rhinitis, sinusitis, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergy, body odor, diaphoresis, flu-like syndrome, infection, injury, moniliasis, thirst, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Angina, apraxia, AV block, bone marrow depression, deep vein thrombosis, dehydration, delirium, delusion, diabetes mellitus, dyskinesia, eosinophilia, erythema multiforme, euphoria, granulocytopenia, hepatic failure, hepatitis, hyperammonemia/encephalopathy (with or without valproate therapy), hyperesthesia, hyperthermia (severe), hypokalemia, hypotension, lymphadenopathy, lymphopenia, maculopathy, manic reaction, neuropathy, oligohydrosis, pancreatitis, pancytopenia, paranoid reaction, pemphigus, photosensitivity, pulmonary embolism, renal tubular acidosis, Stevens-Johnson syndrome, suicidal behavior, suicide, suicidal ideation, syndrome of acute myopia/secondary angle-closure glaucoma, tongue edema, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to topiramate or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and decrease the dose in patients with renal dysfunction; use with caution in patients allergic to sulfa drugs and in patients with hepatic impairment. Cognitive dysfunction, psychiatric disturbances (mood disorders), and sedation (somnolence or fatigue) may occur with use; incidence may be related to rapid titration and higher doses; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). May also cause paresthesia, dizziness, and ataxia. The most common adverse effects of topiramate observed in children include the following: Anorexia, cognitive problems, dizziness, fatigue, fever, flushing, headache, mood problems, parethesia, somnolence, and weight loss; neuropsychiatric and cognitive adverse effects were reported with a lower incidence in children than adults.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hyperammonemia with or without encephalopathy has been reported with topiramate monotherapy or when topiramate was used concurrently with valproic acid; use with caution in patients with inborn errors of metabolism or decreased hepatic mitochondrial activity; these patients may be at increased risk. Pediatric patients &lt;24 months of age may be at increased risk for topiramate associated hyperammonemia, especially when used concurrently with valproic acid. Monitor all patients for lethargy, vomiting, or unexplained changes in mental status. Hypothermia [core body temperature &lt;35&deg;C (95&deg;F)] has been reported with concomitant use of topiramate and valproic acid; symptoms may include lethargy, confusion, coma, or alteration in other major organ system (eg, cardiovascular or respiratory); may occur with or without associated hyperammonemia, and may develop after topiramate initiation or dosage increase; discontinuation of topiramate or valproic acid may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1055781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hyperchloremic metabolic acidosis may occur in patients receiving topiramate. Topiramate may decrease serum bicarbonate concentrations (average decrease of 4 mEq/L at dose of 400 mg/day in adults and 6 mg/kg/day in children), due to inhibition of carbonic anhydrase and increased renal bicarbonate loss. Bicarbonate loss may be severe (serum bicarbonate &lt;10 mEq/L) in rare cases. In pediatric clinical trials for adjunctive treatment of seizures, persistent decreases in serum bicarbonate occurred in 67% of patients receiving topiramate (versus 10% of those receiving placebo). Markedly low serum bicarbonate values were reported in 11% of pediatric patients receiving topiramate (versus 0% of those receiving placebo). In pediatric monotherapy trials, persistent decreases in serum bicarbonate occurred in 9% of patients receiving 50 mg/day and 25% of patients receiving 400 mg/day. Markedly low serum bicarbonate values were reported in 1% to 6% of pediatric patients receiving topiramate monotherapy. The risk of topiramate-induced metabolic acidosis may be increased in patients with predisposing conditions (eg, diarrhea, status epilepticus, renal dysfunction, severe respiratory disorders, ketogenic diet, surgery) or concurrent treatment with other drugs that may cause acidosis. Metabolic acidosis may be more common and more severe in infants and children &lt;2 years of age with up to 45% of patients receiving 25 mg/kg/day developing metabolic acidosis in clinical trials. Reductions in Z scores (from baseline) for length, weight, and head circumference were observed in infants and toddlers who received long-term topiramate (for up to 1 year) for intractable partial epilepsy; reductions in Z scores for length and weight correlated to the severity of metabolic acidosis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Serum bicarbonate should be monitored at baseline and periodically during topiramate therapy. Patients should also be monitored for symptoms of metabolic acidosis (eg, hyperventilation, fatigue, anorexia, stupor, cardiac arrhythmias) and for potential complications of chronic acidosis (eg, nephrolithiasis, rickets, and reduced growth rates). Dose reduction or discontinuation (by tapering the dose) should be considered in patients with persistent or severe metabolic acidosis. If treatment is continued, alkali supplementation should be considered.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     An ocular syndrome (characterized by secondary acute angle closure glaucoma and acute myopia) has been reported in adult and pediatric patients. Symptoms generally occur within 1 month of treatment initiation and include an acute decrease in visual acuity and/or ocular pain. Ophthalmologic findings may include increased IOP, anterior chamber shallowing, ocular hyperemia, mydriasis, and supracilliary effusion with anterior displacement of lens and iris. Patients experiencing blurred vision and/or eye pain should contact their physician immediately. Primary treatment of this syndrome is discontinuation of topiramate as soon as possible, based on physician judgment. If left untreated, this syndrome may cause serious damage to the eye, including permanent vision loss.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Rare, but significant, reports of oligohydrosis (decreased sweating) and hyperthermia have occurred in patients receiving topiramate. Most cases occurred in children, and were associated with vigorous exercise and/or high environmental temperatures. Due to the potential for serious sequelae, the use of preventative strategies (hydration before and during exercise or exposure to warm temperatures) is recommended. Monitor patients, especially pediatric patients, for decreased sweating and hyperthermia, especially in warm or hot weather. Use topiramate with caution in patients receiving drugs that predispose to heat-related disorders (eg, anticholinergic agents, carbonic anhydrase inhibitors).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Do not abruptly discontinue therapy in patients with or without a history of epilepsy or seizures; withdraw gradually to lessen the chance for seizures or increased seizure frequency; in pediatric epilepsy clinical trials, doses were gradually withdrawn over 2-8 weeks; in adult trials, daily doses were decreased in weekly intervals by 50-100 mg in epilepsy patients and by 25-50 mg in adult patients with migraines; monitor patients carefully if rapid withdrawal of topiramate is medically required. CNS adverse effects are common; nephrolithiasis (kidney stones) or paresthesia (usually tingling of extremities) may occur; avoid use with alcohol, CNS depressants, or carbonic anhydrase inhibitors; avoid use of ketogenic diet (may increase risk of nephrolithiasis)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Antiepileptic drugs (AEDs) increase the risk of suicidal behavior and ideation in patients receiving these medications for any indication. Pooled analyses of placebo-controlled trials involving 11 different AEDs (regardless of indication) showed a twofold increased risk of suicidal thoughts or behavior (estimated incidence rate: 0.43% in AED treated patients compared to 0.24% of patients receiving placebo); increased risk was observed as early as 1 week after initiation of AED and continued through duration of trials (most trials &le;24 weeks); risk did not vary significantly by age (age range: 5&ndash;100 years). Consider risks and benefits of AEDs before prescribing. Monitor all patients receiving an AED for emergence of suicidal thoughts or behavior, thoughts of self-harm, any unusual changes in behavior or mood, or the emergence or worsening of depressive symptoms; notify healthcare provider immediately if symptoms or concerning behavior occur.",
"     <b>",
"      Note:",
"     </b>",
"     The FDA requires a Medication Guide for all antiepileptic drugs informing patients of this risk.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F229235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F229174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Carbonic Anhydrase Inhibitors may decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Carbonic Anhydrase Inhibitors may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergic Agents: May enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Barbiturate): Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Anticonvulsants (Barbiturate). Specifically, osteomalacia and rickets.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Anticonvulsants (Hydantoin). Specifically, osteomalacia and rickets.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Topiramate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Management: Avoid concurrent use of different carbonic anhydrase inhibitors if possible.  Monitor patients closely for the occurrence of kidney stones and with regards to severity of metabolic acidosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Topiramate may decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Risk appears greatest for higher topiramate doses (200 mg/day or greater).  Some have recommended using at least 50 mcg/day of ethinyl estradiol, but the effectiveness of this is unclear.  Consider a nonhormonal form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Topiramate may decrease the serum concentration of Contraceptives (Progestins).  Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May enhance the adverse/toxic effect of Topiramate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Carbonic Anhydrase Inhibitors may increase the serum concentration of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Topiramate. Topiramate may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Topiramate may increase the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypokalemic effect of Topiramate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Memantine: Carbonic Anhydrase Inhibitors may decrease the excretion of Memantine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Carbonic Anhydrase Inhibitors may diminish the therapeutic effect of Methenamine.  Management: Consider avoiding this combination. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Topiramate. Topiramate may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Primidone. Specifically, osteomalacia and rickets. Carbonic Anhydrase Inhibitors may decrease the serum concentration of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate. Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Topiramate may enhance the adverse/toxic effect of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1055800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food may decrease the rate but not the extent of absorption; ketogenic diet may increase risk of nephrolithiasis",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F229176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F229191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topiramate was found to be teratogenic in animal studies. Based on limited data, topiramate was found to cross the placenta. An increase risk of oral clefts (cleft lip and/or palate) has been observed following first trimester exposure. Data, from the North American Antiepileptic Drug (NAAED) Pregnancy Registry, reported that the prevalence of oral clefts was 1.4% for infants exposed to topiramate during the first trimester of pregnancy, versus 0.38% to 0.55% for infants exposed to other antiepileptic drugs and 0.07% with no exposure. Hypospadias and other congenital anomalies have also been reported. Although not evaluated during pregnancy, metabolic acidosis may be induced by topiramate. In general, metabolic acidosis during pregnancy may result in adverse effects and fetal death. Pregnant women and their newborns should be monitored for metabolic acidosis.  Maternal serum concentrations may decrease during the second and third trimesters of pregnancy therefore therapeutic drug monitoring should be considered in pregnant women who require therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to topiramate during pregnancy are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency, duration, and severity of seizure episodes or migraine headaches; renal function; monitor serum electrolytes including baseline and periodic serum bicarbonate, symptoms of metabolic acidosis, complications of chronic acidosis (eg, nephrolithiasis, rickets, and reduced growth rates); monitor body temperature and for decreased sweating, especially in warm or hot weather; monitor serum ammonia concentration in patients with unexplained lethargy, vomiting, or mental status changes; intraocular pressure, symptoms of secondary angle closure glaucoma; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1055793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not applicable; plasma topiramate concentrations have not been shown to correlate with clinical efficacy",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exact mechanism unknown; efficacy for epilepsy and migraine prophylaxis may be due to blockade of voltage-dependent sodium channels, potentiation of GABA (an inhibitory neurotransmitter) and antagonism of kainate activation of glutamate (an excitatory amino acid) subtype receptors; also inhibits carbonic anhydrase (minor effect)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Sprinkle capsule is bioequivalent to tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes extensively into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 0.6-0.8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 15% to 41%; percent protein bound decreases as blood concentrations increase",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minor amounts metabolized in liver via hydroxylation, hydrolysis, and glucuronidation; percentage of dose metabolized in liver and clearance are increased in patients receiving enzyme inducers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Tablet: 80% (relative to a prepared solution)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 19-23 hours (mean 21 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults with renal impairment: 59 &plusmn; 11 hours (n=7)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 2 hours; range: 1.4-4.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 70% of dose excreted unchanged in urine; may undergo renal tubular reabsorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 4-17 years: &sim;50% higher than adults (per kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 20-30 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Renal impairment: Reduced",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hepatic impairment: May be reduced",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Significantly hemodialyzed; dialysis clearance: 120 mL/minute (4-6 times higher than in adults with normal renal function); supplemental doses may be required",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/31/8694?source=see_link\">",
"      see \"Topiramate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each prescription and refill of topiramate. Antiepileptic agents may increase the risk of suicidal thoughts and behavior; notify physician if you feel more depressed or have thoughts of suicide or self harm. Before taking this medication, inform physician if you have any of the following conditions: Liver or kidney problems, kidney stones, lung or breathing problems, eye problems, glaucoma, bone problems, growth problems, diarrhea, history of metabolic acidosis, depression, mood problems, suicidal thoughts or behavior, are receiving a ketogenic diet, or will be having surgery. Report the use of other medications, nonprescription medications, and herbal or natural products to your physician and pharmacist. Topiramate may decrease the effectiveness of birth control pills; talk to your doctor about using an alternative, nonhormonal form of contraception.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Take topiramate everyday as prescribed; do not change dose or discontinue without physician's advice; if a dose is missed, take it as soon as possible; however, if you are within 6 hours of your next dose, skip the missed dose and take your scheduled dose as usual; if a dose is skipped, do",
"     <b>",
"      not",
"     </b>",
"     double the next dose. Do not abruptly discontinue therapy (an increase in seizure activity may result). Contact physician immediately if blurred vision or eye pain occur, as these can lead to blindness if not treated right away. Ensure adequate fluid intake to avoid kidney stone formation and to help prevent dehydration and hyperthermia before and during exercise or exposure to warm temperatures. May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. Avoid alcohol. Report worsening of seizure activity or loss of seizure control.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F11509771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 6 mg/mL topiramate oral suspension may be made with tablets and one of two different vehicles (a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;, or a mixture of Simple Syrup, NF and methylcellulose 1% with parabens). Crush six 100 mg tablets in a mortar and reduce to a fine powder. Add a small amount of methylcellulose gel and mix to a uniform paste (",
"     <b>",
"      Note:",
"     </b>",
"     Use a small amount of methylcellulose gel when using the 1:1 Ora-Sweet&reg; and Ora-Plus&reg; mixture as the vehicle; use 10 mL methylcellulose 1% with parabens when using Simple Syrup, NF as the vehicle); mix while adding the chosen vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     100 mL; transfer to a graduated cylinder; rinse mortar with vehicle, and add quantity of vehicle sufficient to make 100 mL. Store in plastic prescription bottles; label \"shake well\" and \"refrigerate\". Stable for 90 days refrigerated (preferred) or at room temperature.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brandes JL, Saper JR, Diamond M, et al, &ldquo;Topiramate for Migraine Prevention: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(8):965-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/60/21448/abstract-text/14982912/pubmed\" id=\"14982912\" target=\"_blank\">",
"        14982912",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doose DR, Walker SA, Gisclon LG, et al, &ldquo;Single-Dose Pharmacokinetics and Effect of Food on the Bioavailability of Topiramate, a Novel Antiepileptic Drug,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1996, 36(10):884-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/60/21448/abstract-text/ 8930774 /pubmed\" id=\" 8930774 \" target=\"_blank\">",
"        8930774",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Filippi L, la Marca G, Fiorini P, et al, \"Topiramate Concentrations in Neonates Treated With Prolonged Whole Body Hypothermia for Hypoxic Ischemic Encephalopathy,\"",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2009, 50(11):2355-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/60/21448/abstract-text/19744111/pubmed\" id=\"19744111\" target=\"_blank\">",
"        19744111",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Filippi L, Poggi C, la Marca G, et al, \"Oral Topiramate in Neonates With Hypoxic Ischemic Encephalopathy Treated With Hypothermia: A Safety Study,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2010, 157(3):361-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/60/21448/abstract-text/20553846/pubmed\" id=\"20553846\" target=\"_blank\">",
"        20553846",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glauser TA, &ldquo;Preliminary Observations on Topiramate in Pediatric Epilepsies,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1997, 38(Suppl 1):S37-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/60/21448/abstract-text/ 9092958 /pubmed\" id=\" 9092958 \" target=\"_blank\">",
"        9092958",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glauser TA, &ldquo;Topiramate Use in Pediatric Patients,&rdquo;",
"      <i>",
"       Can J Neurol Sci",
"      </i>",
"      , 1998, 25(3):S8-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/60/21448/abstract-text/9706734 /pubmed\" id=\"9706734 \" target=\"_blank\">",
"        9706734",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glauser TA, Clark PO, and Strawsburg R, &ldquo;A Pilot Study of Topiramate in the Treatment of Infantile Spasms,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1998, 39(12):1324-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/60/21448/abstract-text/9860068/pubmed\" id=\"9860068\" target=\"_blank\">",
"        9860068",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hershey AD, Powers SW, Vockell AL, et al, &ldquo;Effectiveness of Topiramate in the Prevention of Childhood Headaches,&rdquo;",
"      <i>",
"       Headache",
"      </i>",
"      , 2002, 42(8):810-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/60/21448/abstract-text/12390646 /pubmed\" id=\"12390646 \" target=\"_blank\">",
"        12390646",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pellock JM, &ldquo;Managing Pediatric Epilepsy Syndromes With New Antiepileptic Drugs,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1999, 104(5 Pt 1):1106-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/60/21448/abstract-text/10545555 /pubmed\" id=\"10545555 \" target=\"_blank\">",
"        10545555",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sachdeo RC, &ldquo;Topiramate. Clinical Profile in Epilepsy,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1998, 34(5):335-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/60/21448/abstract-text/9592618/pubmed\" id=\"9592618\" target=\"_blank\">",
"        9592618",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12851 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-B09A38F648-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_60_21448=[""].join("\n");
var outline_f20_60_21448=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229206\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229207\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055790\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12675768\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055783\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229180\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229165\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874884\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055795\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055786\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055794\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229250\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229248\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055798\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055782\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055781\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229235\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229174\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055800\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229176\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229191\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055789\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055793\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055780\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055797\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055788\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11509771\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12851\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12851|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=related_link\">",
"      Topiramate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/31/8694?source=related_link\">",
"      Topiramate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_60_21449="Cesarean delivery: Postoperative issues";
var content_f20_60_21449=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cesarean delivery: Postoperative issues",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/60/21449/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/60/21449/contributors\">",
"     Vincenzo Berghella, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/60/21449/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/60/21449/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/60/21449/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/60/21449/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/60/21449/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic will review the postoperative care of women who have undergone cesarean delivery and discuss potential sequelae of this procedure. Preoperative and intraoperative issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8282?source=see_link\">",
"     \"Cesarean delivery: Preoperative issues\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14682?source=see_link\">",
"     \"Cesarean delivery: Technique\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the immediate postoperative period, the woman is monitored for evidence of uterine atony, excessive vaginal or incisional bleeding, and oliguria. Blood pressure is monitored to assess for hypo or hypertension, which could be signs of intraabdominal bleeding or preeclampsia, respectively.",
"   </p>",
"   <p>",
"    Patient controlled opioid analgesia followed by oral nonsteroidal antiinflammatory drugs provides adequate pain relief for most women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39977?source=see_link&amp;anchor=H22#H22\">",
"     \"Anesthesia for cesarean delivery\", section on 'Postoperative analgesia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no evidence that routine urine culture or a trial of catheter clamping is useful before removal of the bladder catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mother can be instructed in ways to hold her newborn to avoid contact with the incision; lying on her side or a 'football hold' may be used, or a pillow may be placed over the incision and under the infant so the direct contact with the incision is minimized. Heavy lifting and lifting from a squat position confer the greatest increases in intraabdominal pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. These activities should probably be minimized in the first one to two weeks of wound healing, although there are no data regarding the impact of various intraabdominal pressures on wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early ambulation (when the effects of anesthesia have abated) and oral intake (within four to eight hours of surgery) are encouraged. Randomized trials have shown that these interventions enhance the return of bowel function [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/6-11\">",
"     6-11",
"    </a>",
"    ], presumably by stimulating the gastrocolic reflex.",
"   </p>",
"   <p>",
"    The usual",
"    <span class=\"nowrap\">",
"     drugs/procedures",
"    </span>",
"    associated with cesarean birth are not a contraindication to breastfeeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=see_link\">",
"     \"Principles of medication use during lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routine postoperative hemoglobin testing is not necessary in asymptomatic patients after planned cesarean delivery, as the information does lead to improved outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/12\">",
"     12",
"    </a>",
"    ]. There are no studies evaluating such testing after cesareans performed during labor.",
"   </p>",
"   <p>",
"    In a clean surgical wound, the epithelial cells migrate downward to meet deep in the dermis. Migration ceases when the layer is rejuvenated; this is normally completed within 48 hours of surgery. This superficial layer of epithelium creates a barrier to bacteria and other foreign bodies. However, it is very thin, easily traumatized, and gives little tensile strength. Based on these principles of wound healing, we remove staples about three to four days post-operatively if the skin incision was transverse, as there is minimal tension on the skin edges, especially postpartum. We would consider keeping the staples in longer (eg, until five to seven days postoperatively) in women with risk factors for wound complications, such as those with diabetes mellitus or obesity. If a vertical incision was performed, the staples are left in place for at least five to seven days, and longer in a patient at high risk of wound complications, since there is more tension on the skin edges of a vertical incision. Adhesive strips may be applied after removal of the staples to help keep the wound edges approximated. In patients who scar easily, the scar that results from staples may be more pronounced than one produced by sutures, particularly if the staples are left in place for prolonged periods (&gt;5 to 15 days, depending upon the location). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=see_link\">",
"     \"Principles of abdominal wall closure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    General issues regarding the postpartum period are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/30/39402?source=see_link\">",
"     \"Overview of postpartum care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major nonanesthesia-related complications related to cesarean delivery are infection, hemorrhage, injury to pelvic organs, and thromboembolic disorders.",
"   </p>",
"   <p>",
"    There are no randomized trials comparing outcomes of planned vaginal versus planned cesarean delivery for the term cephalic gestation. Moderate quality evidence shows that planned cesarean delivery is associated with less maternal hemorrhage, longer maternal hospital stay, and greater mild neonatal respiratory morbidity than planned vaginal delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/13\">",
"     13",
"    </a>",
"    ]. The risks of severe maternal morbidity are generally higher in women with an unplanned cesarean delivery during labor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/21/344?source=see_link\">",
"     \"Cesarean delivery on maternal request\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cesarean delivery in the second stage of labor is associated with slightly higher maternal composite morbidity than cesarean delivery in the first stage of labor; neonatal morbidity rates are similar for first and second stage cesareans [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall risk of developing a postpartum infection is increased after cesarean delivery compared with vaginal birth [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/17\">",
"     17",
"    </a>",
"    ]. Three major causes of postpartum fever after cesarean delivery are summarized here. An overview of the causes (infectious and noninfectious) and treatment of postoperative fever can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19178?source=see_link\">",
"     \"Postoperative fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Endometritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;If prophylactic antibiotics are not administered, postoperative endometritis occurs in up to 35 to 40 percent of patients delivered by cesarean [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/18\">",
"     18",
"    </a>",
"    ]. This rate is as low as 4 to 5 percent after scheduled delivery with intact membranes, and as high as 85 percent after an extended labor with ruptured membranes. Clinical manifestations, diagnosis, and treatment of endometritis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39097?source=see_link\">",
"     \"Postpartum endometritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By comparison, use of prophylactic antibiotics reduces the overall rate of infection by approximately two-thirds. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8282?source=see_link\">",
"     \"Cesarean delivery: Preoperative issues\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The method of placental extraction can also affect the incidence of postpartum endometritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14682?source=see_link&amp;anchor=H20#H20\">",
"     \"Cesarean delivery: Technique\", section on 'Placental extraction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Wound infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wound infection is diagnosed in 2.5 to 16 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/19\">",
"     19",
"    </a>",
"    ], generally four to seven days after the cesarean. In a large case-control study of risk factors for surgical site infection, 5 percent of 1605 low transverse incisions for cesarean delivery became infected [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/20\">",
"     20",
"    </a>",
"    ]. Approximately 40 percent of the infections were diagnosed after hospital discharge, and the major independent risk factor was development of a subcutaneous hematoma (OR 11.6, 95% CI 4.1-33.2). Prophylactic interventions, such as antibiotic administration and good surgical technique, decrease the incidence of wound infection and disruption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14682?source=see_link\">",
"     \"Cesarean delivery: Technique\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early wound infections (in the first 24 to 48 hours) are usually due to group A or B beta-hemolytic streptococcus and are characterized by high fever and cellulitis. Later infections are more likely to be due to Staphylococcus epidermidis or aureus, Escherichia coli, Proteus mirabilis, or cervicovaginal flora [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wound infections associated with cellulitis alone can be treated with a course of a broad-spectrum antibiotic, such as a cephalosporin. Initial treatment of a wound containing pus consists of opening the wound to allow drainage, cleansing with irrigation, sharp debridement as needed, placement of appropriate dressings (eg, alginates, foams and hydrocolloids, dressings containing antiseptics such as antimicrobial honey, cadexomer iodine or silver), and close attention to subsequent wound care. Superficial incisional infections that have been opened can usually be managed without antibiotics.",
"   </p>",
"   <p>",
"    For more severe infections, especially when there is evidence of extension into adjacent tissue or systemic signs, empirical treatment is started using broad spectrum antibiotics with coverage of the expected flora at the site of operation, as well as gram positive cocci from the skin. Definitive antimicrobial treatment is guided by the clinical response of the patient and, when available, results of wound culture and sensitivity. However, wound swab cultures often reveal polymicrobial growth, making it difficult to distinguish colonization from true infection.",
"   </p>",
"   <p>",
"    Wound care products (calcium alginate, enzymatic debriders, films and foams, hydrogel) and negative pressure (vacuum) wound therapy are used as indicated for the type of wound. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=see_link&amp;anchor=H7#H7\">",
"     \"Abdominal surgical incisions: Prevention and treatment of complications\", section on 'Surgical site infection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link\">",
"     \"Negative pressure wound therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Necrotizing fasciitis is rare (0.18 percent of cesarean deliveries) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     OVT and DSPT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of septic pelvic thrombophlebitis (SPT): ovarian vein thrombophlebitis (OVT) and deep septic pelvic thrombophlebitis (DSPT). These two entities share common pathogenic mechanisms and often occur together, but they may differ in their clinical presentations and diagnostic findings.",
"   </p>",
"   <p>",
"    Patients with OVT usually present with fever and abdominal pain within one week after delivery or surgery, and thrombosis of the right ovarian vein is visualized radiographically in about 20 percent of cases. Patients with DSPT usually present within a few days after delivery or surgery with unlocalized fever that persists despite antibiotics, in the absence of radiographic evidence of thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6807?source=see_link\">",
"     \"Septic pelvic thrombophlebitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean blood loss at cesarean is approximately 1000 mL; however, estimates of blood loss are not very reliable [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. About 2 to 3 percent of all patients undergoing cesarean delivery require blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/26\">",
"     26",
"    </a>",
"    ]. Good surgical technique can decrease the incidence of hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14682?source=see_link\">",
"     \"Cesarean delivery: Technique\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemorrhage may be due to uterine atony, placenta accreta, extensive uterine injury, or extension of the incision into the uterine vessels. Lacerations extending into the lateral vagina and broad ligament should be thoroughly evaluated and repaired with meticulous attention to the position of the ureter. It may be necessary to divide the round ligaments and open the broad ligament to isolate and ligate the bleeding vessel. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=see_link\">",
"     \"Overview of postpartum hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Urinary tract or bowel problems",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary and gastrointestinal tract injuries are uncommon, occurring in fewer than 1 percent of pelvic surgical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/27\">",
"     27",
"    </a>",
"    ]. The incidence of bladder injury in a series of almost 15,000 cesareans was 0.28 percent (incidence in primary and repeat cesareans: 0.14 and 0.56 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/28\">",
"     28",
"    </a>",
"    ]. The risk of cystotomy is higher for cesareans performed in the second stage compared to the first stage [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/16\">",
"     16",
"    </a>",
"    ]. Ureteral injury is rare, occurring in less than 0.1 percent of cesareans [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Injury is most likely to occur during creation of the bladder flap or upon entry into the peritoneum. Risk factors for visceral injury include scarring from previous pelvic surgery, unplanned cesarean, and cesarean hysterectomy. The occurrence of bladder injuries may be minimized by avoiding significant bladder distention during surgery (eg, having the patient void preoperatively or use of a catheter), operating as far from the bladder as is feasible, and assuring transparency of the parietal peritoneum before cutting when sharp dissection is necessary.",
"   </p>",
"   <p>",
"    Early diagnosis and immediate repair of urinary tract and bowel injuries are important to prevent serious sequelae, such as sepsis, renal damage, and fistulae. Small cystotomies in the dome of the bladder are easily approached with a two-layer closure of delayed absorbable suture and 4 to 7 days of catheter drainage. However, large cystotomies and those in the posterior wall of the bladder or near the trigone may involve the ureter. Large lateral uterine or cervical extensions may also involve the ureter. In these cases, placement of ureteral stents can aid in both diagnosis and repair, which are performed according to standard procedures described in detail separately.",
"   </p>",
"   <p>",
"    Diagnosis and management of these injuries is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24631?source=see_link&amp;anchor=H5#H5\">",
"     \"Complications of gynecologic surgery\", section on 'Urinary tract injuries'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24631?source=see_link&amp;anchor=H6#H6\">",
"     \"Complications of gynecologic surgery\", section on 'Bowel injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A best practice policy statement on urologic surgery antimicrobial prophylaxis from a panel of the American Urological Association recommended antibiotic prophylaxis for surgery involving entry into urinary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/31\">",
"     31",
"    </a>",
"    ]. The preferred antibiotic was a first or second generation cephalosporin, or an aminoglycoside plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ; alternatives were",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"      ampicillin",
"     </a>",
"     /sulbactam",
"    </span>",
"    or a fluoroquinolone. The recommended duration of therapy was &le;24 hours. Thus, standard antibiotic prophylaxis given prior to cesarean delivery should be adequate prophylaxis in the event of bladder injury (fluoroquinolones should be avoided in pregnant and breastfeeding women).",
"   </p>",
"   <p>",
"    For women in whom a catheter is left in place postoperatively, there is limited evidence of benefit (eg, reduction in bacteriuria) from continuing antimicrobial therapy for the first three postoperative days or until catheter removal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/32\">",
"     32",
"    </a>",
"    ] or giving antibiotic prophylaxis at catheter removal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Ileus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention and management of postoperative ileus are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2586?source=see_link\">",
"     \"Postoperative ileus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postoperative ileus after cesarean delivery may be related to Ogilvie's syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/50/22311?source=see_link\">",
"     \"Acute colonic pseudo-obstruction (Ogilvie's syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Venous thrombosis and embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of postpartum venous thromboembolism was illustrated by two large studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series involving 395,335 women with live births, the incidence of deep vein thrombosis (DVT) (178 per 100,000 births) was approximately four-fold higher after cesarean than after vaginal delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another series of 268,525 births over an 11-year period, pulmonary embolus (but not DVT) was strongly associated with cesarean delivery (19 of 36,470 cesareans compared with 4 of 232,032 vaginal deliveries, or",
"      <span class=\"nowrap\">",
"       52/100,000",
"      </span>",
"      cesareans versus",
"      <span class=\"nowrap\">",
"       1.7/100,000",
"      </span>",
"      vaginal deliveries) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thromboprophylaxis is recommended to decrease the risk of thromboembolism. The type of thromboprophylaxis (mechanical, pharmacologic, or both) is based on patient-specific risk factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8282?source=see_link&amp;anchor=H15#H15\">",
"     \"Cesarean delivery: Preoperative issues\", section on 'Thromboembolism prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Wound disruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disruption (or opening) of the cesarean laparotomy wound is not uncommon, especially in women with risk factors (eg, obesity, diabetes, history of wound disruption, vertical incision, etc) or infection. The rate of wound disruption in an uninfected wound has been reported to be 1.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/21\">",
"     21",
"    </a>",
"    ]. Fascial dehiscence is uncommon (0.3 percent of cesarean deliveries)",
"   </p>",
"   <p>",
"    Reclosure (ie, secondary closure) with sutures is preferable to healing by secondary intention; healing time is significantly faster (up to two to three weeks versus several weeks to months) and with fewer office visits [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/23,36\">",
"     23,36",
"    </a>",
"    ]. Reclosure with permeable adhesive tape may be both faster and associated with less pain than reclosure with sutures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/37\">",
"     37",
"    </a>",
"    ]. Optimal timing of reclosure is controversial, but probably four to six days after disruption is reasonable if the wound is not infected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=see_link\">",
"     \"Abdominal surgical incisions: Prevention and treatment of complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Psychological outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the studies attempting to evaluate maternal psychological outcomes after vaginal versus planned and unplanned cesarean have reported that women who deliver by cesarean express less satisfaction with their birth experience, are less likely to breastfeed, and take longer before their first interaction with their newborn [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/38\">",
"     38",
"    </a>",
"    ]. In addition, some women have strong feelings of loss, failure, and anger [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These differences are likely related, at least in part, to the anxiety associated with medical and obstetrical complications necessitating abdominal delivery (especially unplanned abdominal delivery); the stress, pain, and fatigue associated with major surgery; and the psychological status of the parturient. Improved psychological outcomes may be realized by realistic preparation for childbirth, maternal involvement in decision making, and attention to the specific needs of the woman who is both postpartum and postoperative [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Fetal and neonatal risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cesarean delivery is usually performed for the benefit of the fetus, there are also fetal risks associated with cesarean birth. These risks include iatrogenic prematurity and birth trauma; the latter occurs in 0.4 to 3 percent of cesareans and consists mostly of mild lacerations related to emergency delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/40-44\">",
"     40-44",
"    </a>",
"    ]. The frequency of birth trauma by mode of delivery is illustrated in the table (",
"    <a class=\"graphic graphic_table graphicRef63989 \" href=\"UTD.htm?29/26/30124\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Transient tachypnea of the newborn (TTN) is more common after scheduled or planned cesarean birth, probably because mechanisms to reabsorb lung fluid have not been initiated. In a review of 29,669 deliveries, the incidence of TTN was about three times higher after planned cesarean than after vaginal delivery (3.1 versus 1.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/45\">",
"     45",
"    </a>",
"    ]. Cesarean delivery has also been reported to be a modest risk factor for respiratory distress syndrome (RDS), particularly if the cesarean was performed in a nonlaboring patient [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/46\">",
"     46",
"    </a>",
"    ]. However, this study did not clearly discriminate between TTN and RDS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32804?source=see_link\">",
"     \"Transient tachypnea of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Maternal mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant proportion of the surgical mortality (and morbidity) of cesarean delivery is related to the underlying medical and obstetrical factors that necessitated the surgical delivery in the first place. In addition, since many planned vaginal deliveries are ultimately delivered by cesarean, these cases need to be taken into account when reporting the mortality and morbidity of vaginal birth.",
"   </p>",
"   <p>",
"    These relationships were illustrated in a study from the Netherlands of deliveries between 1983 and 1992 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/47\">",
"     47",
"    </a>",
"    ]. The risk of dying after vaginal birth was 0.04 per 1000 vaginal births compared to 0.53 per 1000 cesarean births; however, the risk of dying directly attributable to cesarean was much lower, 0.13 per 1000 operations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/21/344?source=see_link&amp;anchor=H12#H12\">",
"     \"Cesarean delivery on maternal request\", section on 'Potential disadvantages and risks of planned cesarean'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The case fatality rate associated with general anesthesia is higher than with regional techniques, estimated at 32 and 1.9 maternal deaths per million live births, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39977?source=see_link\">",
"     \"Anesthesia for cesarean delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     LONG-TERM RISKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term risk of morbidity significantly increases with the number of cesarean deliveries performed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Abnormal placentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cesarean delivery increases the risk of abnormal placentation in future pregnancies (",
"    <a class=\"graphic graphic_table graphicRef51302 \" href=\"UTD.htm?24/26/25003\">",
"     table 2",
"    </a>",
"    ). A meta-analysis (n = 3.7 million women) reported the baseline frequency of placenta previa was 1 in 200 deliveries; however, in women with at least one prior cesarean, the risk of development of placenta previa in a subsequent pregnancy was two to three times higher than at baseline, and the risk increased with the number of prior cesarean births [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35032?source=see_link\">",
"     \"Clinical features, diagnosis, and course of placenta previa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The higher rate of placenta previa is of concern, due to the inherent risks of this disorder and because of the increased frequency of placenta accreta in women with placenta previa and a prior hysterotomy. There is an increased risk of placenta accreta with increasing numbers of prior cesarean deliveries even in the absence of placenta previa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8311?source=see_link\">",
"     \"Clinical features and diagnosis of placenta accreta, increta, and percreta\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the increased risks of abnormal placentation, experts recommend that women who have had a cesarean delivery should have their placental site determined by ultrasound in future pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Placental abruption is another example of a placental abnormality that occurs more often in women with a prior cesarean birth [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]; however, the risk of abruption does not appear to increase with increasing numbers of prior cesarean deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=see_link\">",
"     \"Placental abruption: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Unexplained stillbirth",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of cesarean delivery on future stillbirth is controversial. A 2013 systematic review and meta-analysis reported a significant positive association between cesarean delivery and stillbirth anytime in a subsequent gestation; the significant association was present for both explained stillbirth (OR 2.1) and unexplained stillbirth (OR 1.47) (but not unspecified stillbirth) and for primiparous women (OR 1.3) (but not multiparous women) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/58\">",
"     58",
"    </a>",
"    ]. However, the analysis excluded the largest published study, which included almost 1.8 million singleton second births in women with no underlying medical conditions and fetuses with no structural or chromosomal abnormalities and found no association between previous cesarean and future term fetal demise [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/59\">",
"     59",
"    </a>",
"    ]. In this study, the fetal death rates at term in those with and without a previous cesarean delivery were 0.7 and 0.8 per 1000 births, respectively. In the entire cohort of over 11 million singleton births (second and subsequent births), the fetal death rates at term for women with and without a previous cesarean were 0.4 and 0.6 per 1000 births, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Subfertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several series have reported that women whose first birth is by cesarean are less likely to have a subsequent pregnancy than women whose first birth is a spontaneous vaginal delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. This association appears to be due to confounding factors that affected both the need for cesarean delivery and the choice of subsequent pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. There is also some evidence that subfertile women are more likely to deliver by cesarean and that women who deliver by cesarean take longer to conceive future pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/65\">",
"     65",
"    </a>",
"    ]. However, there is no strong evidence of a causal relationship between cesarean delivery and subfertility [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Scar complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, complications develop in the scars resulting from hysterotomy or abdominal incision:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Hysterotomy scar pregnancy",
"      </strong>",
"      &mdash; Ectopic pregnancy in a previous hysterotomy (cesarean) scar occurs in about 1 in 2000 pregnancies and 6 percent of ectopic pregnancies among women with a prior cesarean delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/67\">",
"       67",
"      </a>",
"      ]. Risk does not appear to be related to the number of cesarean deliveries. The pregnancy is located in the scar outside of the uterine cavity and surrounded by myometrium and connective tissue. Implantation in this location is believed to occur because the embryo migrates through a defect within the scar. Symptoms and diagnosis are similar to tubal ectopic pregnancy. There are no data on the role of the interval between the previous cesarean delivery and hysterotomy scar pregnancy occurrence or the effect of wound closure technique on its occurrence. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16457?source=see_link\">",
"       \"Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The overall rate of ectopic pregnancy is not increased after cesarean delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Numbness or pain",
"      </strong>",
"      &mdash; Branches of the ilioinguinal nerve and the iliohypogastric nerve are severed by transverse abdominal incisions. This often causes a lasting numbness in the region around the scar. Less commonly, patients have a lasting, radiating, invalidating pain due to nerve entrapment [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/69-73\">",
"       69-73",
"      </a>",
"      ]. The diagnostic triad of nerve entrapment after surgery includes: (1) typical burning or lancinating pain near the incision that radiates to the area supplied by the nerve, (2) clear evidence of impaired sensory perception of the nerve, and (3) pain relieved by local infiltration with an anesthetic [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/71\">",
"       71",
"      </a>",
"      ]. Treatment involves surgical repair of the scar with resection of the compromised nerve or nerve block [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/74\">",
"       74",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3129?source=see_link\">",
"       \"Nerve injury associated with pelvic surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Incisional endometriosis",
"      </strong>",
"      &mdash; Incisional endometriosis is another very rare complication of cesarean delivery. It presents as a tender palpable mass in the incision [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/75,76\">",
"       75,76",
"      </a>",
"      ]. The mass increases during menstruation and is associated with cyclic or continuous pain. Differential diagnosis includes incisional hernia. The diagnosis and management of endometriosis at unusual sites is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=see_link&amp;anchor=H8#H8\">",
"       \"Pathogenesis, clinical features, and diagnosis of endometriosis\", section on 'Sites'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Uterine rupture in a subsequent term pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of uterine rupture is higher in women who undergo trial of labor after cesarean delivery (TOLAC) and lower in women who undergo elective repeat cesarean delivery (ERCD). The incidence varies depending on the type and location of the prior uterine incision. (See",
"    <a class=\"medical medical_review\" href=\"./uterine-rupture-after-previous-cesarean-delivery?source=see_link\">",
"     \"Uterine rupture after previous cesarean delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Adhesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal surgery is associated with long-term risks from development of clinically significant adhesions, which can be completely asymptomatic or can cause significant morbidity and mortality as a result of strangulation, obstruction, and necrosis of bowel; infertility;",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    organ injury during repeat abdominal surgery. Formation of adhesions is common after cesarean delivery, and the extent and density increase with increasing numbers of repeat cesarean deliveries: the reported prevalence of adhesions is 12 to 46 percent of women at their second cesarean and 26 to 75 percent of women at their third cesarean [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/77-81\">",
"     77-81",
"    </a>",
"    ]. The rate of bowel obstruction after cesarean delivery is much lower, ranging from 0.5 to 9 per 1000 cesarean deliveries, with the highest risk in women who have undergone multiple cesarean deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. There is no high quality evidence to support the use of adhesion barriers or closure of the peritoneum to prevent complications from adhesions after cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21449/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14682?source=see_link&amp;anchor=H27#H27\">",
"     \"Cesarean delivery: Technique\", section on 'Adhesion barriers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14682?source=see_link&amp;anchor=H28#H28\">",
"     \"Cesarean delivery: Technique\", section on 'Peritoneum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     TRIAL OF LABOR AFTER A CESAREAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;After a cesarean delivery, the surgeon should describe the uterine incision in the operative note and discuss with the patient the feasibility of a trial of labor in a future pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=see_link\">",
"     \"Choosing the route of delivery after cesarean birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     REPEAT CESAREAN DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues relating to repeat cesarean delivery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37862?source=see_link\">",
"     \"Repeat cesarean delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/21/16723?source=see_link\">",
"       \"Patient information: C-section (cesarean delivery) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=see_link\">",
"       \"Patient information: C-section (cesarean delivery) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major short-term complications related to cesarean delivery are infection, hemorrhage, injury to pelvic organs, and thromboembolic disorders. The major long-term risks are abnormal placentation and issues relating to route of delivery in future pregnancies. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/1\">",
"      Horowitz E, Yogev Y, Ben-Haroush A, et al. Urine culture at removal of indwelling catheter after cesarean section. Int J Gynaecol Obstet 2004; 85:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/2\">",
"      Griffiths R, Fernandez R. Strategies for the removal of short-term indwelling urethral catheters in adults. Cochrane Database Syst Rev 2007; :CD004011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/3\">",
"      Weir LF, Nygaard IE, Wilken J, et al. Postoperative activity restrictions: any evidence? Obstet Gynecol 2006; 107:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/4\">",
"      Gerten KA, Richter HE, Wheeler TL 2nd, et al. Intraabdominal pressure changes associated with lifting: implications for postoperative activity restrictions. Am J Obstet Gynecol 2008; 198:306.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/5\">",
"      Minig L, Trimble EL, Sarsotti C, et al. Building the evidence base for postoperative and postpartum advice. Obstet Gynecol 2009; 114:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/6\">",
"      Kramer RL, Van Someren JK, Qualls CR, Curet LB. Postoperative management of cesarean patients: the effect of immediate feeding on the incidence of ileus. Obstet Gynecol 1996; 88:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/7\">",
"      Soriano D, Dulitzki M, Keidar N, et al. Early oral feeding after cesarean delivery. Obstet Gynecol 1996; 87:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/8\">",
"      Mangesi L, Hofmeyr GJ. Early compared with delayed oral fluids and food after caesarean section. Cochrane Database Syst Rev 2002; :CD003516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/9\">",
"      Izbizky GH, Minig L, Sebastiani MA, Ota&ntilde;o L. The effect of early versus delayed postcaesarean feeding on women's satisfaction: a randomised controlled trial. BJOG 2008; 115:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/10\">",
"      Patolia DS, Hilliard RL, Toy EC, Baker B. Early feeding after cesarean: randomized trial. Obstet Gynecol 2001; 98:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/11\">",
"      Orji EO, Olabode TO, Kuti O, Ogunniyi SO. A randomised controlled trial of early initiation of oral feeding after cesarean section. J Matern Fetal Neonatal Med 2009; 22:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/12\">",
"      Horowitz E, Yogev Y, Ben-Haroush A, et al. Routine hemoglobin testing following an elective Cesarean section: is it necessary? J Matern Fetal Neonatal Med 2003; 14:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/13\">",
"      National Institutes of Health state-of-the-science conference statement: Cesarean delivery on maternal request March 27-29, 2006. Obstet Gynecol 2006; 107:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/14\">",
"      Armson BA. Is planned cesarean childbirth a safe alternative? CMAJ 2007; 176:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/15\">",
"      Declercq E, Barger M, Cabral HJ, et al. Maternal outcomes associated with planned primary cesarean births compared with planned vaginal births. Obstet Gynecol 2007; 109:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/16\">",
"      Alexander JM, Leveno KJ, Rouse DJ, et al. Comparison of maternal and infant outcomes from primary cesarean delivery during the second compared with first stage of labor. Obstet Gynecol 2007; 109:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/17\">",
"      Leth RA, M&oslash;ller JK, Thomsen RW, et al. Risk of selected postpartum infections after cesarean section compared with vaginal birth: a five-year cohort study of 32,468 women. Acta Obstet Gynecol Scand 2009; 88:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/18\">",
"      Duff P. Pathophysiology and management of postcesarean endomyometritis. Obstet Gynecol 1986; 67:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/19\">",
"      Owen J, Andrews WW. Wound complications after cesarean sections. Clin Obstet Gynecol 1994; 37:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/20\">",
"      Olsen MA, Butler AM, Willers DM, et al. Risk factors for surgical site infection after low transverse cesarean section. Infect Control Hosp Epidemiol 2008; 29:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/21\">",
"      Martens MG, Kolrud BL, Faro S, et al. Development of wound infection or separation after cesarean delivery. Prospective evaluation of 2,431 cases. J Reprod Med 1995; 40:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/22\">",
"      Roberts S, Maccato M, Faro S, Pinell P. The microbiology of post-cesarean wound morbidity. Obstet Gynecol 1993; 81:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/23\">",
"      Sarsam SE, Elliott JP, Lam GK. Management of wound complications from cesarean delivery. Obstet Gynecol Surv 2005; 60:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/24\">",
"      Ueland K. Maternal cardiovascular dynamics. VII. Intrapartum blood volume changes. Am J Obstet Gynecol 1976; 126:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/25\">",
"      Larsson C, Saltvedt S, Wiklund I, et al. Estimation of blood loss after cesarean section and vaginal delivery has low validity with a tendency to exaggeration. Acta Obstet Gynecol Scand 2006; 85:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/26\">",
"      Rouse DJ, MacPherson C, Landon M, et al. Blood transfusion and cesarean delivery. Obstet Gynecol 2006; 108:891.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Lower urinary tract operative injuries. ACOG educational bulletin 238, American College of Obstetricians and Gynecologists, Washington, DC 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/28\">",
"      Phipps MG, Watabe B, Clemons JL, et al. Risk factors for bladder injury during cesarean delivery. Obstet Gynecol 2005; 105:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/29\">",
"      Eisenkop SM, Richman R, Platt LD, Paul RH. Urinary tract injury during cesarean section. Obstet Gynecol 1982; 60:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/30\">",
"      Rajasekar D, Hall M. Urinary tract injuries during obstetric intervention. Br J Obstet Gynaecol 1997; 104:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/31\">",
"      Wolf JS Jr, Bennett CJ, Dmochowski RR, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 2008; 179:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/32\">",
"      Ni&euml;l-Weise BS, van den Broek PJ. Antibiotic policies for short-term catheter bladder drainage in adults. Cochrane Database Syst Rev 2005; :CD005428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/33\">",
"      Pfefferkorn U, Lea S, Moldenhauer J, et al. Antibiotic prophylaxis at urinary catheter removal prevents urinary tract infections: a prospective randomized trial. Ann Surg 2009; 249:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/34\">",
"      Simpson EL, Lawrenson RA, Nightingale AL, Farmer RD. Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database. BJOG 2001; 108:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/35\">",
"      Gherman RB, Goodwin TM, Leung B, et al. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol 1999; 94:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/36\">",
"      Wechter ME, Pearlman MD, Hartmann KE. Reclosure of the disrupted laparotomy wound: a systematic review. Obstet Gynecol 2005; 106:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/37\">",
"      Harris, RL, Magann, EF, Sullivan, DL, Meeks, GR. Extrafascial wound dehiscence: secondary closure with suture versus noninvasive adhesive bandage. J pelvic Surg 1995; 1:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/38\">",
"      DiMatteo MR, Morton SC, Lepper HS, et al. Cesarean childbirth and psychosocial outcomes: a meta-analysis. Health Psychol 1996; 15:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/39\">",
"      Clement S. Psychological aspects of caesarean section. Best Pract Res Clin Obstet Gynaecol 2001; 15:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/40\">",
"      Nielsen TF, H&ouml;keg&aring;rd KH. Cesarean section and intraoperative surgical complications. Acta Obstet Gynecol Scand 1984; 63:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/41\">",
"      Dessole S, Cosmi E, Balata A, et al. Accidental fetal lacerations during cesarean delivery: experience in an Italian level III university hospital. Am J Obstet Gynecol 2004; 191:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/42\">",
"      Gerber, AH. Int J Obstet Gynecol 1974; 12:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/43\">",
"      Smith JF, Hernandez C, Wax JR. Fetal laceration injury at cesarean delivery. Obstet Gynecol 1997; 90:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/44\">",
"      Alexander JM, Leveno KJ, Hauth J, et al. Fetal injury associated with cesarean delivery. Obstet Gynecol 2006; 108:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/45\">",
"      Levine EM, Ghai V, Barton JJ, Strom CM. Mode of delivery and risk of respiratory diseases in newborns. Obstet Gynecol 2001; 97:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/46\">",
"      Gerten KA, Coonrod DV, Bay RC, Chambliss LR. Cesarean delivery and respiratory distress syndrome: does labor make a difference? Am J Obstet Gynecol 2005; 193:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/47\">",
"      Schuitemaker N, van Roosmalen J, Dekker G, et al. Maternal mortality after cesarean section in The Netherlands. Acta Obstet Gynecol Scand 1997; 76:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/48\">",
"      Hawkins JL, Koonin LM, Palmer SK, Gibbs CP. Anesthesia-related deaths during obstetric delivery in the United States, 1979-1990. Anesthesiology 1997; 86:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/49\">",
"      Clark EA, Silver RM. Long-term maternal morbidity associated with repeat cesarean delivery. Am J Obstet Gynecol 2011; 205:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/50\">",
"      Lyell DJ. Adhesions and perioperative complications of repeat cesarean delivery. Am J Obstet Gynecol 2011; 205:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/51\">",
"      Ananth CV, Smulian JC, Vintzileos AM. The association of placenta previa with history of cesarean delivery and abortion: a metaanalysis. Am J Obstet Gynecol 1997; 177:1071.",
"     </a>",
"    </li>",
"    <li>",
"     Royal College of Obstetricians and Gynaecologists (RCOG). Prevention and management of postpartum haemorrhage. www.rcog.org.uk (Accessed on January 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/53\">",
"      Lydon-Rochelle M, Holt VL, Easterling TR, Martin DP. First-birth cesarean and placental abruption or previa at second birth(1). Obstet Gynecol 2001; 97:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/54\">",
"      Getahun D, Oyelese Y, Salihu HM, Ananth CV. Previous cesarean delivery and risks of placenta previa and placental abruption. Obstet Gynecol 2006; 107:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/55\">",
"      Yang Q, Wen SW, Oppenheimer L, et al. Association of caesarean delivery for first birth with placenta praevia and placental abruption in second pregnancy. BJOG 2007; 114:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/56\">",
"      Jackson S, Fleege L, Fridman M, et al. Morbidity following primary cesarean delivery in the Danish National Birth Cohort. Am J Obstet Gynecol 2012; 206:139.e1.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Consensus Development Conference Statement. NIH Consensus Development Conference: Vaginal Birth After Cesarean: New Insights. March 8&ndash;10, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/58\">",
"      O'Neill SM, Kearney PM, Kenny LC, et al. Caesarean delivery and subsequent stillbirth or miscarriage: systematic review and meta-analysis. PLoS One 2013; 8:e54588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/59\">",
"      Bahtiyar MO, Julien S, Robinson JN, et al. Prior cesarean delivery is not associated with an increased risk of stillbirth in a subsequent pregnancy: analysis of U.S. perinatal mortality data, 1995-1997. Am J Obstet Gynecol 2006; 195:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/60\">",
"      Hall MH, Campbell DM, Fraser C, Lemon J. Mode of delivery and future fertility. Br J Obstet Gynaecol 1989; 96:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/61\">",
"      Jolly J, Walker J, Bhabra K. Subsequent obstetric performance related to primary mode of delivery. Br J Obstet Gynaecol 1999; 106:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/62\">",
"      Collin SM, Marshall T, Filippi V. Caesarean section and subsequent fertility in sub-Saharan Africa. BJOG 2006; 113:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/63\">",
"      Smith GC, Wood AM, Pell JP, Dobbie R. First cesarean birth and subsequent fertility. Fertil Steril 2006; 85:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/64\">",
"      Toll&aring;nes MC, Melve KK, Irgens LM, Skjaerven R. Reduced fertility after cesarean delivery: a maternal choice. Obstet Gynecol 2007; 110:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/65\">",
"      Murphy DJ, Stirrat GM, Heron J, ALSPAC Study Team. The relationship between Caesarean section and subfertility in a population-based sample of 14 541 pregnancies. Hum Reprod 2002; 17:1914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/66\">",
"      Eijsink JJ, van der Leeuw-Harmsen L, van der Linden PJ. Pregnancy after Caesarean section: fewer or later? Hum Reprod 2008; 23:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/67\">",
"      Rotas MA, Haberman S, Levgur M. Cesarean scar ectopic pregnancies: etiology, diagnosis, and management. Obstet Gynecol 2006; 107:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/68\">",
"      O'Neill S, Khashan A, Kenny L, et al. Caesarean section and subsequent ectopic pregnancy: a systematic review and meta-analysis. BJOG 2013; 120:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/69\">",
"      Huikeshoven FJ, Dukel L. [The bikini incision: nice, but not without painful complications]. Ned Tijdschr Geneeskd 1998; 142:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/70\">",
"      Tosun K, Sch&auml;fer G, Leonhartsberger N, et al. Treatment of severe bilateral nerve pain after Pfannenstiel incision. Urology 2006; 67:623.e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/71\">",
"      Stulz P, Pfeiffer KM. Peripheral nerve injuries resulting from common surgical procedures in the lower portion of the abdomen. Arch Surg 1982; 117:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/72\">",
"      Sippo WC, Burghardt A, Gomez AC. Nerve entrapment after Pfannenstiel incision. Am J Obstet Gynecol 1987; 157:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/73\">",
"      Loos MJ, Scheltinga MR, Mulders LG, Roumen RM. The Pfannenstiel incision as a source of chronic pain. Obstet Gynecol 2008; 111:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/74\">",
"      Kim DH, Murovic JA, Tiel RL, Kline DG. Surgical management of 33 ilioinguinal and iliohypogastric neuralgias at Louisiana State University Health Sciences Center. Neurosurgery 2005; 56:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/75\">",
"      Gunes M, Kayikcioglu F, Ozturkoglu E, Haberal A. Incisional endometriosis after cesarean section, episiotomy and other gynecologic procedures. J Obstet Gynaecol Res 2005; 31:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/76\">",
"      Blanco RG, Parithivel VS, Shah AK, et al. Abdominal wall endometriomas. Am J Surg 2003; 185:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/77\">",
"      Tulandi T, Agdi M, Zarei A, et al. Adhesion development and morbidity after repeat cesarean delivery. Am J Obstet Gynecol 2009; 201:56.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/78\">",
"      Soltan MH, Al Nuaim L, Khashoggi T, et al. Sequelae of repeat cesarean sections. Int J Gynaecol Obstet 1996; 52:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/79\">",
"      Makoha FW, Felimban HM, Fathuddien MA, et al. Multiple cesarean section morbidity. Int J Gynaecol Obstet 2004; 87:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/80\">",
"      Morales KJ, Gordon MC, Bates GW Jr. Postcesarean delivery adhesions associated with delayed delivery of infant. Am J Obstet Gynecol 2007; 196:461.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/81\">",
"      Uygur D, Gun O, Kelekci S, et al. Multiple repeat caesarean section: is it safe? Eur J Obstet Gynecol Reprod Biol 2005; 119:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/82\">",
"      Andolf E, Thorsell M, K&auml;ll&eacute;n K. Cesarean delivery and risk for postoperative adhesions and intestinal obstruction: a nested case-control study of the Swedish Medical Birth Registry. Am J Obstet Gynecol 2010; 203:406.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/83\">",
"      Silver RM, Landon MB, Rouse DJ, et al. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol 2006; 107:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/84\">",
"      Al-Sunaidi M, Tulandi T. Adhesion-related bowel obstruction after hysterectomy for benign conditions. Obstet Gynecol 2006; 108:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21449/abstract/85\">",
"      Bates GW Jr, Shomento S. Adhesion prevention in patients with multiple cesarean deliveries. Am J Obstet Gynecol 2011; 205:S19.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4459 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-4F9416D058-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_60_21449=[""].join("\n");
var outline_f20_60_21449=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Endometritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Wound infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - OVT and DSPT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Urinary tract or bowel problems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Ileus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Venous thrombosis and embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Wound disruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Psychological outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Fetal and neonatal risks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Maternal mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      LONG-TERM RISKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Abnormal placentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Unexplained stillbirth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Subfertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Scar complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Uterine rupture in a subsequent term pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      TRIAL OF LABOR AFTER A CESAREAN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      REPEAT CESAREAN DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4459\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4459|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/26/30124\" title=\"table 1\">",
"      Birth trauma by delivery type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/26/25003\" title=\"table 2\">",
"      Risk of placental abnormality by number of cesareans",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16457?source=related_link\">",
"      Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=related_link\">",
"      Abdominal surgical incisions: Prevention and treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/50/22311?source=related_link\">",
"      Acute colonic pseudo-obstruction (Ogilvie's syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39977?source=related_link\">",
"      Anesthesia for cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/21/344?source=related_link\">",
"      Cesarean delivery on maternal request",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8282?source=related_link\">",
"      Cesarean delivery: Preoperative issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14682?source=related_link\">",
"      Cesarean delivery: Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=related_link\">",
"      Choosing the route of delivery after cesarean birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8311?source=related_link\">",
"      Clinical features and diagnosis of placenta accreta, increta, and percreta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35032?source=related_link\">",
"      Clinical features, diagnosis, and course of placenta previa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24631?source=related_link\">",
"      Complications of gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=related_link\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3129?source=related_link\">",
"      Nerve injury associated with pelvic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/30/39402?source=related_link\">",
"      Overview of postpartum care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=related_link\">",
"      Overview of postpartum hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/21/16723?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=related_link\">",
"      Placental abruption: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19178?source=related_link\">",
"      Postoperative fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2586?source=related_link\">",
"      Postoperative ileus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39097?source=related_link\">",
"      Postpartum endometritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=related_link\">",
"      Principles of abdominal wall closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37862?source=related_link\">",
"      Repeat cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6807?source=related_link\">",
"      Septic pelvic thrombophlebitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32804?source=related_link\">",
"      Transient tachypnea of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./uterine-rupture-after-previous-cesarean-delivery?source=related_link\">",
"      Uterine rupture after previous cesarean delivery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_60_21450="Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis";
var content_f20_60_21450=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/60/21450/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/60/21450/contributors\">",
"     William P Fay, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/60/21450/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/60/21450/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/60/21450/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/60/21450/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/60/21450/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemorrhagic and thrombotic disorders are largely mediated by congenital or acquired abnormalities of blood coagulation, platelet number, or platelet function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .) Congenital and acquired abnormalities of the fibrinolytic system, which are less common, can also be responsible for excessive bleeding or thrombosis, and will be discussed here.",
"   </p>",
"   <p>",
"    Discussions of the fibrinolytic system as a prognostic factor in patients with breast cancer as well as in those with cardiovascular disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23193?source=see_link\">",
"     \"Fibrinolytic markers and cardiovascular risk\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=see_link\">",
"     \"Measurement of prognostic factors in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE FIBRINOLYTIC SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key components of the blood fibrinolytic system are illustrated in the figure (",
"    <a class=\"graphic graphic_figure graphicRef81428 \" href=\"UTD.htm?30/24/31118\">",
"     figure 1",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of hemostasis\", section on 'Clot elimination and fibrinolysis'",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Plasminogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasminogen circulates in plasma at a concentration of approximately 2 microM, and is the central zymogen of the fibrinolytic system. Under the action of plasminogen activators (t-PA and u-PA, described below), plasminogen is converted to plasmin, a serine protease that degrades fibrin. The plasminogen molecule contains specific lysine binding sites, which mediate interaction with its target (fibrin) and major inhibitor (alpha-2-antiplasmin).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Tissue-type plasminogen activator",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue-type plasminogen activator (t-PA) is secreted by vascular endothelial cells and circulates in plasma in trace concentrations. It is primarily responsible for catalyzing the degradation of intravascular fibrin by converting plasminogen to plasmin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Urinary-type plasminogen activator",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary-type plasminogen activator (u-PA, urokinase) is secreted by a variety of cell types, including non-vascular cells. It is important not only in triggering fibrin degradation, but also in activating plasminogen to plasmin on cell surfaces following binding to its receptor, u-PAR [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/3\">",
"     3",
"    </a>",
"    ], where it can either degrade or activate a variety of proteins that play key roles in cell function and migration.",
"   </p>",
"   <p>",
"    Plasmin activity is regulated not only by these two plasminogen activators, but also by the following inhibitors of fibrinolysis:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Plasminogen activator inhibitor-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasminogen activator inhibitor-1 (PAI-1) is present in plasma in trace concentrations and is secreted by multiple cell types, including vascular endothelium and smooth muscle cells. It is the primary inhibitor of both t-PA and u-PA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. By this action, PAI-1 suppresses plasmin formation and fibrinolysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23193?source=see_link&amp;anchor=H3#H3\">",
"     \"Fibrinolytic markers and cardiovascular risk\", section on 'Plasminogen activator inhibitor type 1'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Alpha-2-antiplasmin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha-2-antiplasmin (alpha-2-plasmin inhibitor) is produced in the liver and is abundant in plasma (1 microM), where it is the major, if not the sole, inhibitor of plasmin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/7\">",
"     7",
"    </a>",
"    ]. Plasmin released into the circulation is rapidly inactivated by alpha-2-antiplasmin. However, alpha-2-antiplasmin is present in lower concentrations in plasma than is plasminogen (2 microM). Therefore, intense plasminogen activation (eg, during administration of thrombolytic drugs such as streptokinase) can deplete circulating alpha-2-antiplasmin, generate free plasmin, and produce a systemic fibrinolytic state.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Thrombin activatable fibrinolysis inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombin activatable fibrinolysis inhibitor (TAFI) is a procarboxypeptidase that circulates in plasma. It is activated by the thrombin-thrombomodulin complex and cleaves C-terminal lysine residues from fibrin fragments (to which plasminogen binds with high affinity), thereby disrupting recruitment of plasminogen to the partially digested fibrin clot, inhibiting fibrinolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Clinical relevance",
"    </span>",
"    &nbsp;&mdash;&nbsp;To restore vessel patency following hemostasis, the fibrin clot must be organized and removed by the proteolytic enzyme plasmin in conjunction with wound healing and tissue remodeling. Plasminogen, the precursor molecule to plasmin, binds fibrin and t-PA. This ternary complex leads to conversion of the proenzyme plasminogen to active, proteolytic plasmin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Fibrin degradation products and fibrin D-dimer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasmin has broad substrate specificity and, in addition to fibrin, cleaves fibrinogen and a variety of plasma proteins and clotting factors. Plasmin cleaves the polymerized fibrin strand at multiple sites and releases fibrin degradation products (FDPs).",
"   </p>",
"   <p>",
"    One of the major FDPs is D-dimer, which consists of two D domains from adjacent fibrin monomers that have been crosslinked by activated factor XIII. Since D-dimer is generated from cross-linked fibrin, but not from fibrinogen, an elevated plasma concentration of D-dimer indicates recent or ongoing intravascular blood coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     plasminogen/plasminogen-activator",
"    </span>",
"    system is complex, paralleling the coagulation cascade (",
"    <a class=\"graphic graphic_figure graphicRef81428 \" href=\"UTD.htm?30/24/31118\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/9\">",
"     9",
"    </a>",
"    ]. Plasmin activity is regulated by vascular endothelial cells that secrete serine proteases that convert plasminogen to plasmin (ie, tissue- and urinary-type plasminogen activators: t-PA and u-PA, respectively), as well as plasminogen activator inhibitors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal bleeding can result from excessive expression of plasminogen activators or from deficiencies of fibrinolysis inhibitors.",
"     </li>",
"     <li>",
"      Reduced fibrinolytic activity, due to a deficiency of plasminogen or its activators, or excessive expression of fibrinolysis inhibitors, can predispose the patient to thrombosis. This was shown in the Leiden Thrombophilia Study, in which a reduced plasma fibrinolytic potential with clot lysis times above the 90th percentile was associated with an increased risk for DVT (odds ratio 1.9; 95% CI 1.3-2.9) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abnormal expression of specific components of the fibrinolytic system and their roles in human thrombotic and hemorrhagic disorders are discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FIBRINOGEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders of fibrinogen, which are discussed here only briefly, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=see_link\">",
"     \"Disorders of fibrinogen\"",
"    </a>",
"    .) A discussion of fibrinogen and the fibrinolytic system relevant to cardiovascular disease is also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23193?source=see_link\">",
"     \"Fibrinolytic markers and cardiovascular risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Numerous genetic abnormalities of fibrinogen have been reported, ranging from complete fibrinogen deficiency (afibrinogenemia) to qualitative defects in fibrinogen (dysfibrinogenemia). Acquired forms of hypofibrinogenemia and dysfibrinogenemia also can occur. Congenital afibrinogenemia is a rare cause of abnormal bleeding, the severity of which may range from mild to severe. Dysfibrinogenemia has been associated both with hemorrhage and thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=see_link\">",
"     \"Disorders of fibrinogen\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevated plasma fibrinogen levels are strongly associated with human vascular disease. The Northwick Park Heart Study, which prospectively followed 1511 white men for a mean of 10 years, found that elevated plasma fibrinogen was independently associated with subsequent cardiovascular risk [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/11\">",
"     11",
"    </a>",
"    ]. An increase in plasma fibrinogen of approximately 70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    was associated with a 39 percent increase in cardiac death and a 60 percent increase in non-fatal myocardial infarction.",
"   </p>",
"   <p>",
"    It is not known whether elevated plasma fibrinogen plays a causal role in vascular disease progression. Elevated plasma fibrinogen may promote vascular disease by increasing blood viscosity, promoting formation and stability of the fibrin clot, enhancing platelet-platelet interactions, or other mechanisms. However, elevated plasma fibrinogen could simply be a marker of vascular disease that in itself does not contribute to disease progression. For example, it is possible that elevated levels of plasma fibrinogen, an acute phase protein, could result from chronic vascular inflammation, which characterizes atherosclerosis. One meta-analysis concluded that an elevated plasma fibrinogen concentration does not increase coronary heart disease risk [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal experiments have shown that a primary increase in plasma fibrinogen can accelerate thrombus formation and increase blood vessel intimal thickness [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Additional studies are necessary to determine if true causal relationships exist between hyperfibrinogenemia and hemostasis, thrombosis, and vascular disease in humans, and to determine if therapeutic interventions that lower plasma fibrinogen (or improve fibrinolysis) reduce clinical thrombosis and vascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=see_link&amp;anchor=H19#H19\">",
"     \"Cardiovascular benefits and risks of moderate alcohol consumption\", section on 'Antithrombotic effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23193?source=see_link&amp;anchor=H14#H14\">",
"     \"Fibrinolytic markers and cardiovascular risk\", section on 'Therapeutic approaches to impaired fibrinolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PLASMINOGEN DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasminogen deficiency results either from reduced expression of normal plasminogen (hypoplasminogenemia, type I plasminogen deficiency) or from expression of a dysfunctional plasminogen molecule (dysplasminogenemia, type II plasminogen deficiency) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Controversy has existed as to whether plasminogen deficiency is truly a prothrombotic disorder, since individuals with plasminogen deficiency do not uniformly develop thrombosis. One study involving more than 1000 patients with a personal or family history of thrombosis found an overall prevalence of plasminogen deficiency (ie, a plasma level &lt;70 percent of control, measured on at least two separate occasions) of 1.9 percent, with many of the affected individuals also exhibiting an additional thrombophilic defect [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/16\">",
"     16",
"    </a>",
"    ]. This study concluded that plasminogen deficiency was rare in thrombophilic patients, and, as an isolated defect, was not a strong predisposing factor for thrombotic events, either venous or arterial.",
"   </p>",
"   <p>",
"    Perhaps the best data implicating plasminogen deficiency as a potential thrombotic risk factor come from murine studies in which the plasminogen gene has been inactivated by gene targeting strategies. Heterozygous plasminogen deficiency produced no demonstrable phenotypic abnormality, whereas homozygous (ie, complete) plasminogen deficiency produced a marked delay in the clearance of intravascular thrombi, and triggered enhanced fibrin deposition in organs, such as the lungs and liver [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The severity of plasminogen deficiency can vary significantly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe isolated plasminogen deficiency, which can occur secondary to a homozygous or compound heterozygous mutation at the plasminogen gene locus, has not been associated with thrombotic episodes [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/19-21\">",
"       19-21",
"      </a>",
"      ]. Most of the individuals with severe plasminogen deficiency in these studies had low, but detectable (approximately 10 percent of normal) levels of plasminogen activity [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A review of the literature has suggested that heterozygous plasminogen deficiency, as an isolated defect, is not a risk factor for thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Plasminogen deficiency, either homozygous or heterozygous, may promote thrombosis in the presence of other genetic defects, such as the factor V Leiden mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Ligneous conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe plasminogen deficiency can trigger development of ligneous conjunctivitis, a rare ocular disorder characterized by the formation of fibrin-rich pseudomembranes, primarily on the upper tarsal conjunctiva [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/23\">",
"     23",
"    </a>",
"    ]. The pseudomembranes typically are white, yellow-white, or red, and often develop a wood-like consistency. Surgical excisions of pseudomembranes may be necessary. This disorder may also be associated with nasopharyngitis, gingivitis, tracheobronchial obstruction, otitis media, vulvovaginitis, internal hydrocephalus, and defective wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/21,24\">",
"     21,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of forms of medical therapy have been attempted [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/23,25,26\">",
"     23,25,26",
"    </a>",
"    ]. Reports of plasminogen replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/24\">",
"     24",
"    </a>",
"    ], including local delivery of plasminogen in the form of eye drops, appear promising [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PLASMINOGEN ACTIVATORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Documentation of a true deficiency of either t-PA or u-PA is difficult, since these factors are normally present at very low concentration in plasma. In addition, plasma levels of plasminogen activators may be affected by other factors, such as elevated levels of PAI-1. There have been sporadic reports of t-PA deficiency in patients with thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/22\">",
"     22",
"    </a>",
"    ]. However, family members of affected t-PA-deficient individuals generally have not exhibited thrombosis. To date, t-PA gene mutations that produce a deficiency state have not been identified in humans.",
"   </p>",
"   <p>",
"    Mice with isolated, complete t-PA deficiency appear normal, although they exhibit delayed clearance of intravascular thrombi [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/29\">",
"     29",
"    </a>",
"    ]. Mice with isolated, complete u-PA deficiency do not exhibit a defect in clot lysis, but do have minor spontaneous abnormalities, such as non-healing eyelid ulcers. However, mice with complete deficiency of both t-PA and u-PA exhibit striking phenotypic abnormalities, including extensive spontaneous fibrin deposition, along with decreased growth, fertility, and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibodies to t-PA have been described in some patients with thrombosis secondary to the antiphospholipid syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis of the antiphospholipid syndrome\", section on 'Antiphospholipid antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Overexpression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal bleeding due to elevated plasminogen activator levels in the plasma has been reported, but is very rare [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Quebec platelet disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive production of u-PA within the alpha granules of platelets (ie, a gain-of-function defect in fibrinolysis) appears to be responsible for this extremely rare autosomal dominant bleeding disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. This disorder is due to a tandem duplication of PLAU, the u-PA gene [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/35\">",
"     35",
"    </a>",
"    ]. Over-expression of u-PA in platelets appears to inhibit normal hemostasis by several mechanisms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 20 percent of factor V in blood is carried within the alpha granules of platelets, with the balance present in plasma. During platelet activation, factor V and other active compounds carried in alpha granules are released, generating high local concentrations of these agents within the forming clot.",
"     </li>",
"     <li>",
"      Individuals with the Quebec platelet disorder have a severe deficiency of factor V within platelets, due to ectopic over-expression of u-PA within platelet alpha granules. The u-PA activates plasminogen (which is also present within alpha granules) to plasmin, degrading intraplatelet stores of factor V and other hemostasis-related proteins, such as fibrinogen [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Whether the abnormal bleeding in this disorder results from the degradation of platelet hemostatic factors, premature lysis of thrombi due to u-PA release from platelets, or both, is unresolved. However, studies of transgenic mice with platelet-specific over-expression of u-PA suggest that premature clot lysis due to localized release of u-PA from platelets is the predominant cause of bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinically, the Quebec platelet disorder is characterized by moderately severe bleeding that typically occurs 12 to 24 hours after surgery or trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/38\">",
"     38",
"    </a>",
"    ]. An autosomal dominant pattern of inheritance is present. Mild thrombocytopenia is common. Specialized laboratory testing, including analysis of platelet factor V, fibrinogen, and u-PA, can be useful in establishing the diagnosis.",
"   </p>",
"   <p>",
"    In a questionnaire sent to members of large extended family harboring this disorder, bleeding into joints, bleeding longer than 24 hours after dental extraction or deep cuts, poor wound healing, and bruises that spread lower",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    were \"as large or larger than an orange\" were commonly reported by affected family members [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/39\">",
"     39",
"    </a>",
"    ]. When exposed to hemostatic challenges (eg, elective surgery, extensive trauma, dental extraction) they experienced excessive bleeding only when fibrinolytic inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    ) were",
"    <strong>",
"     not",
"    </strong>",
"    employed. Consequently, orally-available fibrinolysis inhibitors can be used to treat subjects with this disorder (see",
"    <a class=\"local\" href=\"#H31\">",
"     'Treatment of abnormal fibrinolysis'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PLASMINOGEN ACTIVATOR INHIBITOR",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasminogen activator inhibitor-1 (PAI-1) deficiency is a rare cause of abnormal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. Two studies reported a kindred with complete PAI-1 deficiency due to a small insertion within the PAI-1 gene that resulted in the production of a non-functional protein [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Heterozygous individuals carrying only a single copy of the defective gene did not exhibit abnormal bleeding, even after surgery. Homozygous deficient individuals exhibited delayed bleeding after surgery or trauma only, suggesting that their initial hemostatic response was normal, but that their clots were lysed prematurely due to excessive fibrinolysis. A second study reported that complete PAI-1 deficiency due to a different mutation in the PAI-1 gene resulted in a severe bleeding disorder and delayed wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Menorrhagia and prolonged wound healing have also been associated with PAI-1 deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/46\">",
"     46",
"    </a>",
"    ]. Orally available fibrinolysis inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    and epsilon-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    , have proven effective in preventing bleeding and enabling PAI-1-deficient individuals to undergo surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=see_link&amp;anchor=H22#H22\">",
"     \"Chronic menorrhagia or anovulatory uterine bleeding\", section on 'Antifibrinolytic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Overexpression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous studies have associated elevated plasma PAI-1 levels with thrombosis, both venous and arterial [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/47\">",
"     47",
"    </a>",
"    ], as well as with the risk of septic shock and multiple organ system failure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. Particular interest has been paid to the potential role of PAI-1 in the pathogenesis of coronary heart disease and myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/51\">",
"     51",
"    </a>",
"    ]. The European Concerted Action on Thrombosis and Disabilities Study prospectively followed 3043 patients with angina pectoris for two years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/52\">",
"     52",
"    </a>",
"    ]. Elevated baseline plasma levels of PAI-1 were associated with an increased incidence of myocardial infarction or sudden cardiac death. However, this association disappeared after correction for factors reflecting insulin resistance, such as obesity, body mass index, and serum triglyceride concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23193?source=see_link&amp;anchor=H3#H3\">",
"     \"Fibrinolytic markers and cardiovascular risk\", section on 'Plasminogen activator inhibitor type 1'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased levels of PAI-1 have been described in children with post-diarrheal hemolytic uremic syndrome; more severely affected patients had a higher plasma PAI-1 concentration, and normalization of plasma levels spontaneously or by peritoneal dialysis was correlated with an improvement in renal function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H14#H14\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Plasminogen activator inhibitor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Insulin stimulates PAI-1 synthesis and secretion by vascular endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/53\">",
"     53",
"    </a>",
"    ]. Therefore, PAI-1 may play an important role in thrombotic complications of atherosclerotic vascular disease, particularly in individuals with insulin resistance. However, further studies are necessary to more precisely define the pathologic consequences of enhanced PAI-1 expression in human subjects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23193?source=see_link&amp;anchor=H9#H9\">",
"     \"Fibrinolytic markers and cardiovascular risk\", section on 'Fibrinolysis and the insulin resistance syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ALPHA-2-ANTIPLASMIN DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deficiency of alpha-2-antiplasmin is a rare congenital bleeding disorder resulting in enhanced plasmin activity and fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/9,54,55\">",
"     9,54,55",
"    </a>",
"    ]. Since the blood coagulation system and platelets function normally in individuals with alpha-2-antiplasmin deficiency, initial blood clotting after trauma is usually normal, with affected individuals typically presenting with delayed bleeding. Prolonged bleeding, mimicking hemophilia, can also occur.",
"   </p>",
"   <p>",
"    The diagnosis is established by measuring plasma levels of alpha-2-antiplasmin with either immunological or functional assays. Plasma transfusion and oral fibrinolysis inhibitors have been used to treat bleeding episodes and to enable surgery.",
"   </p>",
"   <p>",
"    Acquired alpha-2-antiplasmin deficiency has been reported in patients with amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/56\">",
"     56",
"    </a>",
"    ], severe liver disease (impaired synthesis), nephrotic syndrome (increased renal excretion), disseminated intravascular coagulation (increased consumption), acute promyelocytic leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/57,58\">",
"     57,58",
"    </a>",
"    ], malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/58\">",
"     58",
"    </a>",
"    ], abdominal aortic aneurism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/58\">",
"     58",
"    </a>",
"    ], head injury [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/59\">",
"     59",
"    </a>",
"    ], and following the use of thrombolytic agents (excessive utilization) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/60\">",
"     60",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H25\">",
"     'Secondary hyperfibrinolytic states'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombin activatable fibrinolysis inhibitor (TAFI) is a procarboxypeptidase that circulates in plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/61\">",
"     61",
"    </a>",
"    ]. Thrombin, particularly when bound to its endothelial cell-associated receptor, thrombomodulin, cleaves specific bonds within TAFI, converting it to an activated form (TAFIa).",
"   </p>",
"   <p>",
"    TAFIa is a basic carboxypeptidase that cleaves C-terminal lysine residues from fibrin fragments generated during the initial stages of plasmin-mediated fibrinolysis. Since plasminogen binds to C-terminal lysines with high affinity, TAFIa disrupts recruitment of plasminogen to the partially digested fibrin clot, thereby inhibiting fibrinolysis (",
"    <a class=\"graphic graphic_figure graphicRef81428 \" href=\"UTD.htm?30/24/31118\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Enhanced TAFI expression is a potential risk factor for thrombosis, while TAFI deficiency could in theory produce a hemorrhagic defect.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A report from the Leiden Thrombophilia Study found that elevated plasma levels of TAFI (&gt;90th percentile) were more common in patients with deep venous thrombosis (DVT) than in an age- and gender-matched control group, suggesting that elevated plasma TAFI was a risk factor for DVT (relative risk 1.7, 95% CI: 1.1-2.5) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 600 patients with spontaneous (idiopathic) DVT who had completed at least three months of treatment with oral anticoagulants, the relative risk of VTE recurrence was 1.7 (95% CI: 1.1-2.7) among those with plasma TAFI levels &ge;75th percentile compared with those having lower levels [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of 770 venous thrombosis patients and 743 healthy control subjects found that elevated plasma TAFI concentration was associated with increased risk of first venous thromboembolic event, even after unconditional logistic regression analysis was performed to adjust for potential confounding effects of age, gender, body-mass index, and plasma levels of acute phase proteins such as fibrinogen and factor VIII [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A case-control study found that functional plasma TAFI levels &gt;120 percent of normal significantly increased the risk of ischemic stroke (relative risk 5.7, 95% CI: 2.3-14.1) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/65\">",
"       65",
"      </a>",
"      ]. A second study of 136 patients with acute stroke found that plasma TAFI levels fall significantly during the first 72 hours after stroke onset and subsequently return to baseline, and that more severe initial declines were associated with greater stroke severity and poorer long-term outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/66\">",
"       66",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Enhanced fibrinolysis can be a complication of coagulation factor deficiencies, such as in deficiencies of factor VIII, IX, or XI, due to decreased production of thrombin, and consequently a decreased activation of TAFI to TAFIa [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/61,67-69\">",
"       61,67-69",
"      </a>",
"      ]. Therefore, decreased TAFI activation could contribute to the bleeding phenotype associated with coagulation factor deficiencies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link&amp;anchor=H28#H28\">",
"       \"Overview of hemostasis\", section on 'Thrombin-activatable fibrinolysis inhibitor'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the above-mentioned association studies, a cause-and-effect relationship between abnormal TAFI expression and either bleeding or thrombosis has not been firmly established, and further studies are necessary to define the potential role of TAFI in the pathogenesis of human disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     LP(a) LIPOPROTEIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lp(a) lipoprotein is a modified form of low density lipoprotein (LDL) cholesterol that is composed of apoprotein(a) covalently linked by a single interchain disulfide bridge to apolipoprotein B-100. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=see_link&amp;anchor=H2#H2\">",
"     \"Lipoprotein(a) and cardiovascular disease\", section on 'Structure and function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Apoprotein(a) contains a series of domains, referred to as kringles, that each contains a lysine-binding site. Kringles are also present in plasminogen and are responsible for its binding to fibrin and plasminogen receptors. Accordingly, circulating Lp(a) lipoprotein can competitively inhibit binding of plasminogen to the fibrin clot and cell surfaces, thereby inhibiting fibrinolysis and cell-associated plasmin formation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23193?source=see_link&amp;anchor=H10#H10\">",
"     \"Fibrinolytic markers and cardiovascular risk\", section on 'Fibrinolysis and hyperlipoproteinemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lp(a) lipoprotein has a number of other potentially prothrombotic actions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lp(a) lipoprotein enhances expression of PAI-2 in blood monocytes, which would inhibit fibrinolysis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lp(a) lipoprotein binds and inactivates tissue factor pathway inhibitor (TFPI), which could enhance factor VII activation, promoting blood coagulation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis of prospective studies of plasma Lp(a) lipoprotein levels and the subsequent risk of coronary heart disease death or non-fatal myocardial infarction revealed that these cardiac events are 1.6-fold more common in individuals with plasma Lp(a) lipoprotein levels within the top tertile compared with those with levels within the bottom tertile [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=see_link\">",
"     \"Lipoprotein(a) and cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Venous thromboembolism (VTE) also has been associated with elevated plasma Lp(a) lipoprotein levels. One study of nearly 700 consecutive patients with VTE found that serum Lp(a) lipoprotein concentrations &gt;30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    were found in 20 percent of thrombosis patients, but in only 7 percent of healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/73\">",
"     73",
"    </a>",
"    ]. This study, and a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/74\">",
"     74",
"    </a>",
"    ], concluded that a plasma Lp(a) lipoprotein level &gt;30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    is an independent risk factor for VTE. In addition, an elevated Lp(a) lipoprotein may promote the penetrance of other prothrombotic defects, such as the factor V Leiden mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SECONDARY HYPERFIBRINOLYTIC STATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperfibrinolytic states (eg, secondary fibrinolysis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibrinogenolysis) have been reported following a number of disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Secondary fibrinolysis is commonly seen in patients with disseminated intravascular coagulation (DIC), due to the release of t-PA, with subsequent generation of plasmin at the site of vascular injury. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=see_link\">",
"       \"Pathogenesis and etiology of disseminated intravascular coagulation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      DIC, often accompanied by plasminogen activation, reduction in alpha-2-antiplasmin, fibrinolysis, and clinical bleeding is commonly seen in acute promyelocytic leukemia [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/57,58,75\">",
"       57,58,75",
"      </a>",
"      ]. The coagulopathy is aggravated by chemotherapy but promptly responds to therapy with all-trans retinoic acid or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/47/16119?source=see_link\">",
"       arsenic trioxide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/76\">",
"       76",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\", section on 'Disseminated intravascular coagulation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic liver disease, as well as the anhepatic period during orthotopic liver transplantation, can lead to a hyperfibrinolytic state due to decreased clearance of t-PA from the circulation as well as decreased hepatic synthesis of alpha-2-antiplasmin [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/77-81\">",
"       77-81",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link&amp;anchor=H5858379#H5858379\">",
"       \"Coagulation abnormalities in patients with liver disease\", section on 'Hyperfibrinolysis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperfibrinolysis has been reported with a number of malignancies [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/82-84\">",
"       82-84",
"      </a>",
"      ]. Excessive fibrinolysis in prostatic cancer has been attributed to DIC with secondary fibrinolysis, excess production of urinary-type plasminogen activators by the malignant cells,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      secondary reductions in alpha-2-antiplasmin [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/58,85,86\">",
"       58,85,86",
"      </a>",
"      ]. In some reports, treatment with chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/87\">",
"       87",
"      </a>",
"      ] or epsilon-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"       aminocaproic acid",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/85\">",
"       85",
"      </a>",
"      ] has reversed the coagulopathy.",
"     </li>",
"     <li>",
"      Enhanced fibrinolysis can be a complication of coagulation factor deficiencies, such as hemophilia A, due to decreased production of thrombin, and consequently, decreased activation of thrombin activatable fibrinolysis inhibitor [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/61,67-69\">",
"       61,67-69",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Thrombin activatable fibrinolysis inhibitor'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link&amp;anchor=H28#H28\">",
"       \"Overview of hemostasis\", section on 'Thrombin-activatable fibrinolysis inhibitor'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperfibrinolytic states, characterized by depletion of plasma alpha-2-antiplasmin, plasminogen, and fibrinogen, can be induced by non-fibrin-specific plasminogen activators, such as streptokinase and urokinase, used in the treatment of myocardial infarction and other thrombotic disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/60\">",
"       60",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28297?source=see_link&amp;anchor=H21#H21\">",
"       \"Vascular endothelial function and fundamental mechanisms of fibrinolysis (thrombolysis)\", section on 'Thrombolytic therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bleeding is common after cardiopulmonary bypass; its genesis is multifactorial, but may include a component of excessive fibrinolysis that responds to the use of antifibrinolytic agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38537?source=see_link&amp;anchor=H19#H19\">",
"       \"Postoperative complications among patients undergoing cardiac surgery\", section on 'Bleeding'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients suffering from heat stroke have multiple coagulation abnormalities, including increased fibrinolysis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/88,89\">",
"       88,89",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     LABORATORY DIAGNOSIS OF ABNORMAL FIBRINOLYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient with thrombosis or abnormal bleeding, if initial laboratory testing reveals no defects within platelets or the coagulation system, a congenital or acquired defect of fibrinolysis should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link&amp;anchor=H22#H22\">",
"     \"Approach to the adult patient with a bleeding diathesis\", section on 'Diagnostic approach'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link&amp;anchor=H18#H18\">",
"     \"Approach to the child with bleeding symptoms\", section on 'Diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Increased fibrinolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hyperfibrinolytic states are rare and are due to excessive production of plasminogen activators or to decreased production of fibrinolysis inhibitors. A secondary hyperfibrinolytic state with abnormal bleeding can develop in multiple clinical settings, including trauma, malignancy, liver transplantation or failure, cardiopulmonary bypass [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/90,91\">",
"     90,91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperfibrinolysis can be difficult to differentiate clinically from other causes of abnormal bleeding, such as disseminated intravascular coagulation (DIC), which also can involve activation of the fibrinolytic system, and thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS), which is not associated with increased fibrinolysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are a number of laboratory tests that can help to make the distinction among hyperfibrinolysis, DIC, and TTP. These are listed below (",
"      <a class=\"graphic graphic_table graphicRef78455 \" href=\"UTD.htm?16/22/16748\">",
"       table 1",
"      </a>",
"      ). A normal platelet count coupled with a normal level of antithrombin and the absence of schistocytes should favor hyperfibrinolysis over DIC.",
"     </li>",
"     <li>",
"      However, using the tests outlined in this table to make this distinction can still be difficult. Less standard tests, such as the euglobulin lysis time and thromboelastography [",
"      <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/91\">",
"       91",
"      </a>",
"      ], when available, may be helpful in this setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link&amp;anchor=H21#H21\">",
"       \"Approach to the adult patient with a bleeding diathesis\", section on 'Tests for fibrinolysis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Observation of a clinical response to empiric initiation of an anti-fibrinolytic drug can help to establish a clinical diagnosis of hyperfibrinolysis when hyperfibrinolysis is suspected but cannot be conclusively diagnosed via available laboratory tests. However, DIC must be ruled out before such treatment can be safely initiated, as the use of anti-fibrinolytic agents in DIC can result in massive thromboses. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link&amp;anchor=H26#H26\">",
"       \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'General principles'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Euglobulin lysis time",
"    </span>",
"    &nbsp;&mdash;&nbsp;The euglobulin lysis time (ELT) is a simple assay that is used to assess the global function of the plasma fibrinolytic system. Dilution of citrated plasma at low ionic strength and low pH precipitates the euglobulin fraction, a population of proteins that includes fibrinogen, plasminogen, and t-PA, but lacks fibrinolysis inhibitors. The proteins present in the euglobulin fraction are dissolved in buffer, clotted by addition of thrombin, and the time required for the clot to lyse is measured (normal value: 90 to 240 minutes). A shortened ELT is characteristic of a hyperfibrinolytic state. The presence of a shortened ELT in the absence of thrombocytopenia and schistocytosis is characteristic of primary hyperfibrinolysis and can be used to help differentiate this disorder from DIC and TTP (",
"    <a class=\"graphic graphic_table graphicRef78455 \" href=\"UTD.htm?16/22/16748\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10592760\">",
"    <span class=\"h3\">",
"     Thromboelastography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thromboelastography (TEG) involves the measurement of torque on a pin as a cup containing whole blood is rotated at a constant rate. As clot formation begins, the torque increases, and, with clot breakdown from fibrinolysis, the torque decreases. TEG has been successfully utilized as a point of care test within surgical departments, especially in trauma and orthotopic liver transplantation where excessive fibrinolysis may be a major problem [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Antithrombin levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma levels of antithrombin are usually normal in primary hyperfibrinolysis, while they are often decreased in patients with DIC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Reduced fibrinolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypofibrinolysis, which can result from under-expression of plasminogen or its activators, or by over-expression of fibrinolysis inhibitors, can lead to thrombosis.",
"   </p>",
"   <p>",
"    Laboratory-based diagnosis of a hypofibrinolytic state can be difficult for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Levels of plasminogen activators in plasma are very low under normal conditions, making definitive diagnosis of abnormally low levels difficult.",
"     </li>",
"     <li>",
"      Plasma levels of fibrinolysis inhibitors, such as PAI-1, can vary widely among normal individuals. This variability complicates establishing elevated plasma levels of a fibrinolysis inhibitor as the definitive cause of thrombosis in an individual patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These conditions may be associated with a prolonged euglobulin lysis time. Specific thrombotic conditions associated with under-expression of plasminogen or its activators (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Plasminogen deficiency'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H19\">",
"     'Plasminogen activator inhibitor'",
"    </a>",
"    above), or with over-expression of fibrinolysis inhibitors are discussed above (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Thrombin activatable fibrinolysis inhibitor'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H24\">",
"     'Lp(a) lipoprotein'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     TREATMENT OF ABNORMAL FIBRINOLYSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10592881\">",
"    <span class=\"h2\">",
"     Treatment of the underlying disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of abnormal fibrinolysis is initially geared at correcting underlying causes. As an example, if hyperfibrinolysis is secondary to prostate cancer or acute promyelocytic leukemia, successful treatment of the malignancy can restore normal fibrinolytic function (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Secondary hyperfibrinolytic states'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=see_link&amp;anchor=H18#H18\">",
"     \"Initial treatment of acute promyelocytic leukemia in adults\", section on 'Control of coagulopathy'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10592961\">",
"    <span class=\"h2\">",
"     Hypofibrinolytic states",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypofibrinolytic states are generally treated, if necessary, by down-regulating clot formation with anticoagulants, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . Protein replacement therapy, as in the case of plasminogen deficiency, can also be employed (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Plasminogen deficiency'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10593002\">",
"    <span class=\"h2\">",
"     Hyperfibrinolytic states",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrinolysis inhibitors, which disrupt interactions between",
"    <span class=\"nowrap\">",
"     plasminogen/plasmin",
"    </span>",
"    and fibrin, have been used to treat hyperfibrinolytic states, and have also been successfully used to reduce perioperative blood losses (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/92\">",
"     92",
"    </a>",
"    ]. In bleeding patients with the Quebec platelet disorder, platelet transfusions are generally without effect; fibrinolytic inhibitors are reported to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/93-95\">",
"     93-95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of fibrinolytic inhibitors in patients with liver disease and hyperfibrinolysis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link&amp;anchor=H5858379#H5858379\">",
"     \"Coagulation abnormalities in patients with liver disease\", section on 'Hyperfibrinolysis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link&amp;anchor=H5858528#H5858528\">",
"     \"Coagulation abnormalities in patients with liver disease\", section on 'Anti-fibrinolytics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Tranexamic acid and epsilon-aminocaproic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     Tranexamic acid",
"    </a>",
"    and epsilon-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    are lysine analogues that bind to the kringle domains of plasminogen and disrupt interactions between plasminogen (and plasmin) and lysine residues within fibrin. Tranexamic acid binds plasminogen and plasmin more avidly than epsilon-aminocaproic acid does, and may produce a more potent anti-hemorrhagic effect [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These antifibrinolytic agents have been recommended for use in settings where fibrinolysis is prominent, such as when tissues with high fibrinolytic activity are involved (eg, oropharynx, prostate, endometrium). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/14/37097?source=see_link&amp;anchor=H22#H22\">",
"     \"Factor XI deficiency\", section on 'Antifibrinolytic agents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17529?source=see_link&amp;anchor=H16#H16\">",
"     \"Management of abnormal uterine bleeding in adolescents\", section on 'Hemostatic therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of von Willebrand disease\", section on 'Antifibrinolytic therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link&amp;anchor=H5858528#H5858528\">",
"     \"Coagulation abnormalities in patients with liver disease\", section on 'Anti-fibrinolytics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of these agents in patients undergoing coronary artery bypass surgery is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link&amp;anchor=H12#H12\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Antifibrinolytic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Aprotinin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/52/6982?source=see_link\">",
"     Aprotinin",
"    </a>",
"    , a 58 amino acid protein isolated from bovine lung, inhibits plasmin, kallikrein, and other proteases. Aprotinin inhibits fibrinolysis, thrombin generation, and inflammatory responses. Although aprotinin has been successfully used to reduce blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass during coronary artery bypass grafting surgery, its safety relative to other antifibrinolytic drugs has been called into question. The Blood Conservation Using Antifibrinolytics in a Randomized Trial (BART) study randomly assigned 2331 high-risk cardiac surgical patients to receive aprotinin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/60/21450/abstract/97\">",
"     97",
"    </a>",
"    ]. While aprotinin was associated with a reduction in massive bleeding compared with the other two agents, it was also associated with a significantly higher risk of death, which has led to the recommendation that aprotinin not be used to prevent excessive bleeding in cardiac surgery. Due to these concerns, aprotinin was removed from the market by the United States Food and Drug Administration. This subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link&amp;anchor=H12#H12\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Antifibrinolytic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10593045\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       plasminogen/plasminogen-activator",
"      </span>",
"      system, which controls dissolution of the fibrin clot (fibrinolysis), is complex, paralleling the coagulation cascade (",
"      <a class=\"graphic graphic_figure graphicRef81428 \" href=\"UTD.htm?30/24/31118\">",
"       figure 1",
"      </a>",
"      ). Disorders of this system can lead to excessive bleeding or thrombosis, depending upon whether fibrinolysis is increased or decreased, respectively. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'The fibrinolytic system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Congenital disorders of fibrinolysis are uncommon and may include either deficiency or overexpression of the components of the fibrinolytic system. In a patient with thrombosis or abnormal bleeding, if initial laboratory testing reveals no defects within platelets or the coagulation system, a congenital or acquired defect of fibrinolysis should be considered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link&amp;anchor=H22#H22\">",
"       \"Approach to the adult patient with a bleeding diathesis\", section on 'Diagnostic approach'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link&amp;anchor=H18#H18\">",
"       \"Approach to the child with bleeding symptoms\", section on 'Diagnostic approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A secondary hyperfibrinolytic state with abnormal bleeding can develop in multiple clinical settings, including disseminated intravascular coagulation, trauma, malignancy, liver transplantation or failure, and cardiopulmonary bypass. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Secondary hyperfibrinolytic states'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperfibrinolysis can be difficult to differentiate clinically from other causes of abnormal bleeding, especially disseminated intravascular coagulation (DIC), which also can involve activation of the fibrinolytic system (",
"      <a class=\"graphic graphic_table graphicRef78455 \" href=\"UTD.htm?16/22/16748\">",
"       table 1",
"      </a>",
"      ). A shortened euglobulin lysis time",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increased fibrinolysis as demonstrated by thromboelastography provide the best available evidence for the presence of hyperfibrinolysis. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Laboratory diagnosis of abnormal fibrinolysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of abnormal fibrinolysis is initially geared at correcting underlying causes, if possible. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Treatment of abnormal fibrinolysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Hypo",
"      </strong>",
"      fibrinolytic states are generally treated, if necessary, by down-regulating clot formation with anticoagulants such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      . Protein replacement therapy, as in the case of plasminogen deficiency, can also be employed (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Plasminogen deficiency'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      <strong>",
"       Hyper",
"      </strong>",
"      fibrinolytic states are generally treated with the use of fibrinolysis inhibitors (eg, epsilon-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"       aminocaproic acid",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       tranexamic acid",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H10593002\">",
"       'Hyperfibrinolytic states'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/1\">",
"      Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005; 129:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/2\">",
"      Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009; 7:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/3\">",
"      Mazar AP. Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res 2008; 14:5649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/4\">",
"      Gils A, Declerck PJ. The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. Thromb Haemost 2004; 91:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/5\">",
"      Horrevoets AJ. Plasminogen activator inhibitor 1 (PAI-1): in vitro activities and clinical relevance. Br J Haematol 2004; 125:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/6\">",
"      Iwaki T, Urano T, Umemura K. PAI-1, progress in understanding the clinical problem and its aetiology. Br J Haematol 2012; 157:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/7\">",
"      Christiansen VJ, Jackson KW, Lee KN, McKee PA. The effect of a single nucleotide polymorphism on human alpha 2-antiplasmin activity. Blood 2007; 109:5286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/8\">",
"      Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood 2009; 113:2878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/9\">",
"      Stump DC, Taylor FB Jr, Nesheim ME, et al. Pathologic fibrinolysis as a cause of clinical bleeding. Semin Thromb Hemost 1990; 16:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/10\">",
"      Lisman T, de Groot PG, Meijers JC, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005; 105:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/11\">",
"      Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/12\">",
"      Smith GD, Harbord R, Milton J, et al. Does elevated plasma fibrinogen increase the risk of coronary heart disease? Evidence from a meta-analysis of genetic association studies. Arterioscler Thromb Vasc Biol 2005; 25:2228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/13\">",
"      Kerlin B, Cooley BC, Isermann BH, et al. Cause-effect relation between hyperfibrinogenemia and vascular disease. Blood 2004; 103:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/14\">",
"      Machlus KR, Cardenas JC, Church FC, Wolberg AS. Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood 2011; 117:4953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/15\">",
"      Mehta R, Shapiro AD. Plasminogen deficiency. Haemophilia 2008; 14:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/16\">",
"      Demarmels Biasiutti F, Sulzer I, Stucki B, et al. Is plasminogen deficiency a thrombotic risk factor? A study on 23 thrombophilic patients and their family members. Thromb Haemost 1998; 80:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/17\">",
"      Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995; 9:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/18\">",
"      Ploplis VA, Carmeliet P, Vazirzadeh S, et al. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 1995; 92:2585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/19\">",
"      Okamoto A, Sakata T, Mannami T, et al. Population-based distribution of plasminogen activity and estimated prevalence and relevance to thrombotic diseases of plasminogen deficiency in the Japanese: the Suita Study. J Thromb Haemost 2003; 1:2397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/20\">",
"      Tait RC, Walker ID, Conkie JA, et al. Isolated familial plasminogen deficiency may not be a risk factor for thrombosis. Thromb Haemost 1996; 76:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/21\">",
"      Tefs K, Gueorguieva M, Klammt J, et al. Molecular and clinical spectrum of type I plasminogen deficiency: A series of 50 patients. Blood 2006; 108:3021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/22\">",
"      Brandt JT. Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease. Arch Pathol Lab Med 2002; 126:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/23\">",
"      Schuster V, Seregard S. Ligneous conjunctivitis. Surv Ophthalmol 2003; 48:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/24\">",
"      Schott D, Dempfle CE, Beck P, et al. Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency. N Engl J Med 1998; 339:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/25\">",
"      Teresa Sartori M, Saggiorato G, Pellati D, et al. Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis. Thromb Haemost 2003; 90:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/26\">",
"      Schuster V, H&uuml;gle B, Tefs K. Plasminogen deficiency. J Thromb Haemost 2007; 5:2315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/27\">",
"      Watts P, Suresh P, Mezer E, et al. Effective treatment of ligneous conjunctivitis with topical plasminogen. Am J Ophthalmol 2002; 133:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/28\">",
"      Heidemann DG, Williams GA, Hartzer M, et al. Treatment of ligneous conjunctivitis with topical plasmin and topical plasminogen. Cornea 2003; 22:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/29\">",
"      Carmeliet P, Schoonjans L, Kieckens L, et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/30\">",
"      Cugno M, Dominguez M, Cabibbe M, et al. Antibodies to tissue-type plasminogen activator in plasma from patients with primary antiphospholipid syndrome. Br J Haematol 2000; 108:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/31\">",
"      Cugno M, Cabibbe M, Galli M, et al. Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. Blood 2004; 103:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/32\">",
"      Booth NA, Bennett B, Wijngaards G, Grieve JH. A new life-long hemorrhagic disorder due to excess plasminogen activator. Blood 1983; 61:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/33\">",
"      Diamandis M, Paterson AD, Rommens JM, et al. Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes. Blood 2009; 113:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/34\">",
"      Veljkovic DK, Rivard GE, Diamandis M, et al. Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation. Blood 2009; 113:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/35\">",
"      Paterson AD, Rommens JM, Bharaj B, et al. Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene. Blood 2010; 115:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/36\">",
"      Kahr WH, Zheng S, Sheth PM, et al. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood 2001; 98:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/37\">",
"      Kufrin D, Eslin DE, Bdeir K, et al. Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets. Blood 2003; 102:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/38\">",
"      Tracy PB, Giles AR, Mann KG, et al. Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency. J Clin Invest 1984; 74:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/39\">",
"      McKay H, Derome F, Haq MA, et al. Bleeding risks associated with inheritance of the Quebec platelet disorder. Blood 2004; 104:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/40\">",
"      Di&eacute;val J, Nguyen G, Gross S, et al. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood 1991; 77:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/41\">",
"      Lee MH, Vosburgh E, Anderson K, McDonagh J. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood 1993; 81:2357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/42\">",
"      Schleef RR, Higgins DL, Pillemer E, Levitt LJ. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 1989; 83:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/43\">",
"      Minowa H, Takahashi Y, Tanaka T, et al. Four cases of bleeding diathesis in children due to congenital plasminogen activator inhibitor-1 deficiency. Haemostasis 1999; 29:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/44\">",
"      Fay WP, Shapiro AD, Shih JL, et al. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992; 327:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/45\">",
"      Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 1997; 90:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/46\">",
"      Iwaki T, Tanaka A, Miyawaki Y, et al. Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans. J Thromb Haemost 2011; 9:1200.",
"     </a>",
"    </li>",
"    <li>",
"     Eitzman DT, Fay WP, Ginsburg D. Plasminogen activator inhibitor-1. In: Textbook of Coronary Thrombosis and Thrombolysis, Becker RC (Ed), Kluwer Academic Publishing, Norwell, MA 1997. p.65.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/48\">",
"      S&aacute;nchez Miralles A, Reig S&aacute;enz R, Marco Vera P, et al. [Abnormalities in coagulation and fibrinolysis in septic shock with purpura]. An Esp Pediatr 2002; 56:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/49\">",
"      Raaphorst J, Johan Groeneveld AB, Bossink AW, Erik Hack C. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients. Thromb Haemost 2001; 86:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/50\">",
"      Westendorp RG, Hottenga JJ, Slagboom PE. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999; 354:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/51\">",
"      Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 2004; 91:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/52\">",
"      Juhan-Vague I, Pyke SD, Alessi MC, et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/53\">",
"      Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/54\">",
"      Saito H. Alpha 2-plasmin inhibitor and its deficiency states. J Lab Clin Med 1988; 112:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/55\">",
"      Williams EC. Plasma alpha 2-antiplasmin activity. Role in the evaluation and management of fibrinolytic states and other bleeding disorders. Arch Intern Med 1989; 149:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/56\">",
"      Clyne LP, Caldwell AB. Acquired alpha-2 anti-plasmin deficiency secondary to amyloidosis. Thromb Haemost 1987; 58:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/57\">",
"      Schwartz BS, Williams EC, Conlan MG, Mosher DF. Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2-plasmin inhibitor deficiency. Ann Intern Med 1986; 105:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/58\">",
"      Okajima K, Kohno I, Soe G, et al. Direct evidence for systemic fibrinogenolysis in patients with acquired alpha 2-plasmin inhibitor deficiency. Am J Hematol 1994; 45:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/59\">",
"      Kushimoto S, Shibata Y, Yamamoto Y. Implications of fibrinogenolysis in patients with closed head injury. J Neurotrauma 2003; 20:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/60\">",
"      Onundarson PT, Haraldsson HM, Bergmann L, et al. Plasminogen depletion during streptokinase treatment or two-chain urokinase incubation correlates with decreased clot lysability ex vivo and in vitro. Thromb Haemost 1993; 70:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/61\">",
"      Bouma BN, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost 2003; 1:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/62\">",
"      van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95:2855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/63\">",
"      Eichinger S, Sch&ouml;nauer V, Weltermann A, et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004; 103:3773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/64\">",
"      Meltzer ME, Lisman T, de Groot PG, et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/65\">",
"      Santamar&iacute;a A, Oliver A, Borrell M, et al. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke 2003; 34:2387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/66\">",
"      Brouns R, Heylen E, Willemse JL, et al. The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome. J Thromb Haemost 2010; 8:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/67\">",
"      Broze GJ Jr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996; 88:3815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/68\">",
"      Mosnier LO, Lisman T, van den Berg HM, et al. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost 2001; 86:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/69\">",
"      Gr&uuml;newald M, Siegemund A, Gr&uuml;newald A, et al. Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia. Haemophilia 2002; 8:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/70\">",
"      Buechler C, Ullrich H, Ritter M, et al. Lipoprotein (a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes. Blood 2001; 97:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/71\">",
"      Caplice NM, Panetta C, Peterson TE, et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 2001; 98:2980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/72\">",
"      Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/73\">",
"      von Depka M, Nowak-G&ouml;ttl U, Eisert R, et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 2000; 96:3364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/74\">",
"      Sofi F, Marcucci R, Abbate R, et al. Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis. Am J Med 2007; 120:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/75\">",
"      Menell JS, Cesarman GM, Jacovina AT, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999; 340:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/76\">",
"      Zhang X, Zhou H, Wang J, et al. Arsenic trioxide, retinoic acid and Ara-c regulated the expression of annexin II on the surface of APL cells, a novel co-receptor for plasminogen/tissue plasminogen activator. Thromb Res 2002; 106:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/77\">",
"      Hunt BJ, Segal H. Hyperfibrinolysis. J Clin Pathol 1996; 49:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/78\">",
"      Ben-Ari Z, Osman E, Hutton RA, Burroughs AK. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction? Am J Gastroenterol 1999; 94:2977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/79\">",
"      Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis 2002; 22:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/80\">",
"      Bakker CM, Metselaar HJ, Groenland TN, et al. Increased fibrinolysis in orthotopic but not in heterotopic liver transplantation: the role of the anhepatic phase. Transpl Int 1992; 5 Suppl 1:S173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/81\">",
"      Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/82\">",
"      Garc&iacute;a Frade LJ, Sureda A, Torrado MC, Garc&iacute;a Avello A. High plasma urokinase-type plasminogen activator levels are present in patients with acute nonlymphoblastic leukemia. Acta Haematol 1992; 88:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/83\">",
"      Okajima K, Kohno I, Tsuruta J, et al. Direct evidence for systemic fibrinogenolysis in a patient with metastatic prostatic cancer. Thromb Res 1992; 66:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/84\">",
"      Naina HV, Patnaik MM, Ali UA, et al. Systemic fibrinolysis caused by tissue plasminogen activator-producing metastatic breast cancer. J Clin Oncol 2010; 28:e167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/85\">",
"      Cooper DL, Sandler AB, Wilson LD, Duffy TP. Disseminated intravascular coagulation and excessive fibrinolysis in a patient with metastatic prostate cancer. Response to epsilon-aminocaproic acid. Cancer 1992; 70:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/86\">",
"      Shariat SF, Roehrborn CG, McConnell JD, et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007; 25:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/87\">",
"      Sallah S, Gagnon GA. Reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel. Cancer Invest 2000; 18:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/88\">",
"      al-Mashhadani SA, Gader AG, al Harthi SS, et al. The coagulopathy of heat stroke: alterations in coagulation and fibrinolysis in heat stroke patients during the pilgrimage (Haj) to Makkah. Blood Coagul Fibrinolysis 1994; 5:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/89\">",
"      Bouchama A, Bridey F, Hammami MM, et al. Activation of coagulation and fibrinolysis in heatstroke. Thromb Haemost 1996; 76:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/90\">",
"      Rocha E, P&aacute;ramo JA, Montes R, Panizo C. Acute generalized, widespread bleeding. Diagnosis and management. Haematologica 1998; 83:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/91\">",
"      Theusinger OM, Wanner GA, Emmert MY, et al. Hyperfibrinolysis diagnosed by rotational thromboelastometry (ROTEM) is associated with higher mortality in patients with severe trauma. Anesth Analg 2011; 113:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/92\">",
"      Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356:2301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/93\">",
"      Hayward CP, Rivard GE, Kane WH, et al. An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect. Blood 1996; 87:4967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/94\">",
"      Hayward CP. Inherited disorders of platelet alpha-granules. Platelets 1997; 8:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/95\">",
"      Hayward CP, Cramer EM, Kane WH, et al. Studies of a second family with the Quebec platelet disorder: evidence that the degradation of the alpha-granule membrane and its soluble contents are not secondary to a defect in targeting proteins to alpha-granules. Blood 1997; 89:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/96\">",
"      Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999; 57:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/60/21450/abstract/97\">",
"      Fergusson DA, H&eacute;bert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358:2319.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1326 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-D8E73D39BC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_60_21450=[""].join("\n");
var outline_f20_60_21450=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10593045\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE FIBRINOLYTIC SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Plasminogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Tissue-type plasminogen activator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Urinary-type plasminogen activator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Plasminogen activator inhibitor-1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Alpha-2-antiplasmin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Thrombin activatable fibrinolysis inhibitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Clinical relevance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Fibrin degradation products and fibrin D-dimer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FIBRINOGEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PLASMINOGEN DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Ligneous conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PLASMINOGEN ACTIVATORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Overexpression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Quebec platelet disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PLASMINOGEN ACTIVATOR INHIBITOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Overexpression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ALPHA-2-ANTIPLASMIN DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      LP(a) LIPOPROTEIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SECONDARY HYPERFIBRINOLYTIC STATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      LABORATORY DIAGNOSIS OF ABNORMAL FIBRINOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Increased fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Euglobulin lysis time",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10592760\">",
"      - Thromboelastography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Antithrombin levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Reduced fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      TREATMENT OF ABNORMAL FIBRINOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10592881\">",
"      Treatment of the underlying disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10592961\">",
"      Hypofibrinolytic states",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10593002\">",
"      Hyperfibrinolytic states",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Tranexamic acid and epsilon-aminocaproic acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Aprotinin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10593045\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1326\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1326|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/24/31118\" title=\"figure 1\">",
"      Regulation of fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1326|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/22/16748\" title=\"table 1\">",
"      Lab diagnosis fibrinolysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=related_link\">",
"      Approach to the child with bleeding symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=related_link\">",
"      Cardiovascular benefits and risks of moderate alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=related_link\">",
"      Chronic menorrhagia or anovulatory uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=related_link\">",
"      Coagulation abnormalities in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=related_link\">",
"      Disorders of fibrinogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/14/37097?source=related_link\">",
"      Factor XI deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23193?source=related_link\">",
"      Fibrinolytic markers and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=related_link\">",
"      Initial treatment of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=related_link\">",
"      Lipoprotein(a) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17529?source=related_link\">",
"      Management of abnormal uterine bleeding in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=related_link\">",
"      Measurement of prognostic factors in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=related_link\">",
"      Pathogenesis and etiology of disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=related_link\">",
"      Pathogenesis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38537?source=related_link\">",
"      Postoperative complications among patients undergoing cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=related_link\">",
"      Treatment of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28297?source=related_link\">",
"      Vascular endothelial function and fundamental mechanisms of fibrinolysis (thrombolysis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_60_21451="Effector cell populations";
var content_f20_60_21451=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F52815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F52815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Properties of effector cell populations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Property",
"       </td>",
"       <td class=\"subtitle1\">",
"        NK",
"       </td>",
"       <td class=\"subtitle1\">",
"        CTL",
"       </td>",
"       <td class=\"subtitle1\">",
"        NK-like T cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenotype",
"       </td>",
"       <td>",
"        CD3-CD56+CD16+",
"       </td>",
"       <td>",
"        CD3+CD56-CD8+",
"       </td>",
"       <td>",
"        CD3+CD56+CD16-",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Precursor cell",
"       </td>",
"       <td>",
"        NK",
"       </td>",
"       <td>",
"        T",
"       </td>",
"       <td>",
"        T",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antigen specific",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Expandable",
"       </td>",
"       <td>",
"        Limited",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Require IL-2 in vivo",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NK: natural killer cells; CTL: cytotoxic T lymphocytes.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Lu, LPH, Negrin, RS. Biol Blood Marrow Transplant 1997; 3:113.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_60_21451=[""].join("\n");
var outline_f20_60_21451=null;
var title_f20_60_21452="Multiple keratoacanthoma clinical variants";
var content_f20_60_21452=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical variants of multiple keratoacanthomas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Characteristics",
"       </td>",
"       <td class=\"subtitle1\">",
"        Genetic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Generalized eruptive keratoacanthomas of Grzybowski",
"       </td>",
"       <td>",
"        <p>",
"         Presents in 5th to 7th decade",
"        </p>",
"        <p>",
"         Multiple follicular based papules, and ulcerated nodules",
"        </p>",
"        <p>",
"         100s to 1000s of lesions",
"        </p>",
"        <p>",
"         Predilection for the trunk, extremities, and inner mouth",
"        </p>",
"        <p>",
"         Disfigurement due to facial lesions (ectropion)",
"        </p>",
"        <p>",
"         Individual lesions spontaneously regress with scar formation",
"        </p>",
"       </td>",
"       <td>",
"        Sporadic disorder",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Multiple self-healing squamous epithelioma (Ferguson-Smith disease)",
"       </td>",
"       <td>",
"        <p>",
"         Present in 2nd to 3rd decade; mean age of 25",
"        </p>",
"        <p>",
"         Multiple reddish macules that develop into papules and nodules that resemble solitary keratoacanthoma",
"        </p>",
"        <p>",
"         Single lesion to 100s in number",
"        </p>",
"        <p>",
"         Predilection for sites of trauma and sun exposed areas; face, arms",
"        </p>",
"        <p>",
"         Individual lesions involute spontaneously but lesions may recur throughout life",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal dominant",
"        </p>",
"        <p>",
"         Loss of function mutations in TGFBR1 gene",
"        </p>",
"        <p>",
"         Increased in patients with Scottish ancestry",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Multiple familial keratoacanthoma of Witten and Zak",
"       </td>",
"       <td>",
"        <p>",
"         Clinical features of both generalized eruptive keratoacanthomas of Grzybowski and multiple self-healing squamous epithelioma",
"        </p>",
"        <p>",
"         Larger lesions that tend to ulcerate",
"        </p>",
"        <p>",
"         Locally destructive",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"1\">",
"        Muir-Torre Syndrome",
"       </td>",
"       <td>",
"        <p>",
"         May occur in both young and elderly patients",
"        </p>",
"        <p>",
"         Multiple keratoacanthomas",
"        </p>",
"        <p>",
"         Sebaceous tumors",
"        </p>",
"        <p>",
"         Visceral malignancies (genitourinary and gastrointestinal)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal dominant",
"        </p>",
"        <p>",
"         Defect in mismatch repair gene (MSH2 or MLH1)",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_60_21452=[""].join("\n");
var outline_f20_60_21452=null;
var title_f20_60_21453="Spotted fever group rickettsiae";
var content_f20_60_21453=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Spotted fever group rickettsiae",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vectors",
"       </td>",
"       <td class=\"subtitle1\">",
"        Geographic distribution",
"       </td>",
"       <td class=\"subtitle1\">",
"        Severity of symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Rocky mountain spotted fever",
"       </td>",
"       <td rowspan=\"3\">",
"        R. rickettsii",
"       </td>",
"       <td>",
"        <p>",
"         Dermacentor andersoni",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"       </td>",
"       <td>",
"        United States",
"       </td>",
"       <td rowspan=\"3\">",
"        Human - severe to mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D. variabilis",
"       </td>",
"       <td>",
"        Southern Canada",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Rhipicephalus sanguineous ticks",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         Ambylomma ticks",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Mexico",
"        </p>",
"        <p>",
"         Central America",
"        </p>",
"        <p>",
"         Brazil",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rickettsialpox",
"       </td>",
"       <td>",
"        R. akari",
"       </td>",
"       <td>",
"        Allodermanyssus sanguineous (mouse mites)",
"       </td>",
"       <td>",
"        <p>",
"         North America",
"        </p>",
"        <p>",
"         Korea",
"        </p>",
"        <p>",
"         Balkans",
"        </p>",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Mediterranean spotted fever",
"       </td>",
"       <td rowspan=\"2\">",
"        R. conorii",
"       </td>",
"       <td>",
"        R. sanguineous",
"       </td>",
"       <td>",
"        North Africa",
"       </td>",
"       <td rowspan=\"2\">",
"        Mild to severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Haemaphysalis ticks",
"       </td>",
"       <td>",
"        <p>",
"         Kenya",
"        </p>",
"        <p>",
"         Israel",
"        </p>",
"        <p>",
"         Southern Europe",
"        </p>",
"        <p>",
"         Pakistan",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Queensland tick typhus",
"       </td>",
"       <td>",
"        R. australis",
"       </td>",
"       <td>",
"        Ixodes ticks",
"       </td>",
"       <td>",
"        Eastern Australia",
"       </td>",
"       <td>",
"        Mild to moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flinders Island spotted fever",
"       </td>",
"       <td>",
"        R. honei",
"       </td>",
"       <td>",
"        Ticks of several genera",
"       </td>",
"       <td>",
"        <p>",
"         Australia",
"        </p>",
"        <p>",
"         Southeast Asia",
"        </p>",
"        <p>",
"         Northwestern North America",
"        </p>",
"        <p>",
"         Thailand",
"        </p>",
"       </td>",
"       <td>",
"        Mild to moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        African tick bite fever",
"       </td>",
"       <td>",
"        R. africae",
"       </td>",
"       <td>",
"        Amblyomma ticks",
"       </td>",
"       <td>",
"        <p>",
"         Sub-Saharan Africa",
"        </p>",
"        <p>",
"         Caribbean",
"        </p>",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Siberian tick typhus",
"       </td>",
"       <td>",
"        R. sibirica, R. sibirica mongolotimonae",
"       </td>",
"       <td>",
"        Dermacentor ticks",
"       </td>",
"       <td>",
"        <p>",
"         China",
"        </p>",
"        <p>",
"         Russia",
"        </p>",
"        <p>",
"         Southern and Eastern Europe",
"        </p>",
"       </td>",
"       <td>",
"        Mild to moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Japanese spotted fever",
"       </td>",
"       <td>",
"        R. japonica",
"       </td>",
"       <td>",
"        <p>",
"         Dermacentor",
"        </p>",
"        <p>",
"         Haemaphysalis",
"        </p>",
"        <p>",
"         Ixodes ticks",
"        </p>",
"       </td>",
"       <td>",
"        Southwest Japan",
"       </td>",
"       <td>",
"        Mild to severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flea rickettsiosis",
"       </td>",
"       <td>",
"        R. felis",
"       </td>",
"       <td>",
"        Cat fleas",
"       </td>",
"       <td>",
"        <p>",
"         Europe",
"        </p>",
"        <p>",
"         North America",
"        </p>",
"        <p>",
"         South America",
"        </p>",
"        <p>",
"         Africa",
"        </p>",
"        <p>",
"         Asia",
"        </p>",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphangitis-associated rickettsiosis",
"       </td>",
"       <td>",
"        R. sibirica mongolotimonae",
"       </td>",
"       <td>",
"        Hyalomma ticks",
"       </td>",
"       <td>",
"        <p>",
"         China",
"        </p>",
"        <p>",
"         Sub-Saharan Africa",
"        </p>",
"        <p>",
"         France",
"        </p>",
"       </td>",
"       <td>",
"        Mild to moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tick-borne lymphadenopathy",
"       </td>",
"       <td>",
"        R. slovaca",
"       </td>",
"       <td>",
"        Dermacentor ticks",
"       </td>",
"       <td>",
"        Southern and eastern Europe",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        R. parkeri infection",
"       </td>",
"       <td>",
"        R. parkeri",
"       </td>",
"       <td>",
"        Amblyomma ticks",
"       </td>",
"       <td>",
"        United States",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_60_21453=[""].join("\n");
var outline_f20_60_21453=null;
var title_f20_60_21454="Dynamic Y stent";
var content_f20_60_21454=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dynamic Y-stent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 215px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Dynamic&trade; Y stent has a rigid anterior wall comprised of horseshoe-shaped metal struts. The posterior wall is silicone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_60_21454=[""].join("\n");
var outline_f20_60_21454=null;
var title_f20_60_21455="Clinical etiologic classification myoclonus";
var content_f20_60_21455=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F78331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F78331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of myoclonus by clinical syndrome and etiology",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        I. Physiologic myoclonus (normal subjects)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        A. Sleep jerks (eg, hypnic jerks)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        B. Anxiety-induced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        C. Exercise-induced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        D. Hiccough (singultus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        E. Benign infantile myoclonus with feeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        II. Essential myoclonus (primary symptom, nonprogressive history)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        A. Hereditary (autosomal dominant)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        B. Sporadic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        III. Epileptic myoclonus (associated with a chronic seizure disorder or syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        A. Fragments of epilepsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Isolated epileptic myoclonic jerks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Epilepsia partialis continua",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        3. Idiopathic stimulus-sensitive myoclonus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        4. Photosensitive myoclonus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        5. Absences with a minor myoclonic component",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        6. Epilepsy with myoclonic absences",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        B. Childhood myoclonic epilepsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Infantile spasms (West syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Severe myoclonic epilepsy of infancy (Dravet syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        3. Benign myoclonic epilepsy of infancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        4. Lennox-Gastaut syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        5. Myoclonic astatic epilepsy (Doose syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        6. Cryptogenic myoclonus epilepsy (Aicardi)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        7. Juvenile myoclonic epilepsy (Janz syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        C. Familial cortical myoclonic tremor with epilepsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Autosomal dominant cortical myoclonus and epilepsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Benign adult familial myoclonic epilepsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        3. Cortical tremor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        4. Familial adult myoclonic epilepsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        5. Familial cortical myoclonic tremor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        6. Familial cortical tremor with epilepsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        7. Familial essential myoclonus and epilepsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        8. Familial rhythmic cortical myoclonus (tremor) with epilepsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        9. Familial benign myoclonus epilepsy of adult onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        10. Heredofamilial tremor and epilepsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        IV. Symptomatic (secondary) myoclonus (not defined by occurrence of seizures)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        A. Progressive myoclonic epilepsy: Unverricht-Lundborg disease (Baltic myoclonus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        B. Storage disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Lafora body disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. GM2 gangliosidosis (late infantile, juvenile)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        3. Tay-Sachs disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        4. Gaucher disease (noninfantile neuronopathic form)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        5. Krabbe leukodystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        6. Neuronal ceroid lipofuscinosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        7. Sialidosis (types 1 and 2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        C. Spinocerebellar degenerations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Progressive myoclonus ataxia (Ramsay-Hunt cerebellar syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Friedreich ataxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        3. Ataxia-telangiectasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        4. Other spinocerebellar degenerations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        D. Basal ganglia degenerations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Wilson disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Torsion dystonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        3. Pantothenate kinase-associated neurodegeneration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        4. Progressive supranuclear palsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        5. Huntington disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        6. Parkinson disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        7. Multiple system atrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        8. Corticobasal degeneration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        9. Dentatorubral pallidoluysian atrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        E. Dementias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Creutzfeldt-Jakob disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Alzheimer disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        3. Dementia with Lewy bodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        4. Frontotemporal dementia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        5. Rett syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        F. Diffuse infectious/postinfectious/inflammatory disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Subacute sclerosing panencephalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Encephalitis lethargica",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        3. Arbovirus encephalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        4. Herpes simplex encephalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        5. Human T-lymphotropic virus I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        6. Human immunodeficiency virus (HIV)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        7. Postinfectious encephalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        8. Miscellaneous bacteria (Streptococcus, Clostridium, other)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        9. Malaria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        10. Syphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        11. Cryptococcus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        12. Lyme disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        13. Paraneoplastic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        14. Progressive multifocal leukoencephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        G. Metabolic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Hyperthyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Hepatic failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        3. Renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        4. Dialysis syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        5. Hyponatremia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        6. Hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        7. Nonketotic hyperglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        8. Multiple carboxylase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        9. Biotin deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        10. Hypoxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        11. Metabolic alkalosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        12. Vitamin E deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        H. Toxic and drug-induced syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        &bull; Levodopa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        &bull; Psychiatric medications (eg, tricyclic antidepressants, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, lithium)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        &bull; Antibiotics (eg, penicillins, cephalosporins, quinolones)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        &bull; Narcotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        &bull; Anticonvulsants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        &bull; Anesthetics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        &bull; Contrast media",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        &bull; Cardiac medications (eg, calcium channel blockers, antiarrhythmic agents)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        &bull; Drug withdrawal from certain agents (eg, sedatives)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Toxins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        &bull; Bismuth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        &bull; Heavy metals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        &bull; Methyl bromide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        &bull; Dichlorodiphenyltrichloroethane (DDT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        I. Physical encephalopathies (usually static)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Posthypoxic (Lance-Adams)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Post-traumatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        3. Heat stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        4. Electric shock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        5. Decompression injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        J. Focal nervous system damage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Central nervous system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        a. Post-stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        b. Post-thalamotomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        c. Tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        d. Trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        e. Infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        f. Inflammation (eg, multiple sclerosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        g. Mobius syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        h. Developmental",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        i. Idiopathic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Peripheral nervous system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        a. Trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        b. Hematoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        K. Malabsorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Celiac disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Whipple disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        L. Eosinophilia-myalgia syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        M. Opsoclonus-myoclonus syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Idiopathic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Paraneoplastic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        3. Infectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        4. Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        N. Exaggerated startle syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Hereditary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Sporadic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        O. Hashimoto's encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        P. Other multiple system degenerations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Action myoclonus-renal failure syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Mitochondrial disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        3. Allgrove syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        4. DiGeorge syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        5. Membranous lipodystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Q. Primary progressive myoclonus of aging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        R. Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Familial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Sporadic",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Marsden CD, Hallett M, Fahn S. The nosology and pathophysiology of myoclonus. In: Movement Disorders, Marsden CD, Fahn S (Eds), Butterworths, London 1982. p.196.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_60_21455=[""].join("\n");
var outline_f20_60_21455=null;
